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Mesenchymal stem cells in preclinical
cancer cytotherapy: a systematic review
Ioannis Christodoulou1, Maria Goulielmaki1, Marina Devetzi1, Mihalis Panagiotidis2, Georgios Koliakos3
and Vassilis Zoumpourlis1*
Abstract
Mesenchymal stem cells (MSC) comprise a heterogeneous population of rapidly proliferating cells that can be
isolated from adult (e.g., bone marrow, adipose tissue) as well as fetal (e.g., umbilical cord) tissues (termed bone
marrow (BM)-, adipose tissue (AT)-, and umbilical cord (UC)-MSC, respectively) and are capable of differentiation into
a wide range of non-hematopoietic cell types. An additional, unique attribute of MSC is their ability to home to
tumor sites and to interact with the local supportive microenvironment which rapidly conceptualized into MSC-
based experimental cancer cytotherapy at the turn of the century. Towards this purpose, both naïve (unmodified)
and genetically modified MSC (GM-MSC; used as delivery vehicles for the controlled expression and release of
antitumorigenic molecules) have been employed using well-established in vitro and in vivo cancer models, albeit
with variable success. The first approach is hampered by contradictory findings regarding the effects of naïve MSC
of different origins on tumor growth and metastasis, largely attributed to inherent biological heterogeneity of MSC
as well as experimental discrepancies. In the second case, although the anti-cancer effect of GM-MSC is markedly
improved over that of naïve cells, it is yet apparent that some protocols are more efficient against some types of
cancer than others. Regardless, in order to maximize therapeutic consistency and efficacy, a deeper understanding
of the complex interaction between MSC and the tumor microenvironment is required, as well as examination of
the role of key experimental parameters in shaping the final cytotherapy outcome. This systematic review
represents, to the best of our knowledge, the first thorough evaluation of the impact of experimental anti-cancer
therapies based on MSC of human origin (with special focus on human BM-/AT-/UC-MSC). Importantly, we dissect
the commonalities and differences as well as address the shortcomings of work accumulated over the last two
decades and discuss how this information can serve as a guide map for optimal experimental design
implementation ultimately aiding the effective transition into clinical trials.
Keywords: Adult mesenchymal stem cells, Umbilical cord matrix stem cells, Wharton’s jelly, Tumor
microenvironment, Experimental cancer cytotherapy, Gene delivery vehicles
Background
In the turn of the millennium after over four decades of in-
tensive research in the genetics of cancer, an important
paradigm shift has occurred, in which instrumental for the
development of the disease is not only the link between cu-
mulative instability of key genes and the rise of aberrant cell
cycle control, but also the orchestration of a heterogeneous
cell-based stromal network supportive of tumor invasion
and metastasis. This switch in focus has led to the
elucidation of the composition of this microenvironmental
niche and of the interaction dynamics of its multiple cellu-
lar and extracellular components. Concomitant have been
the emergence of the epithelial-to-mesenchymal transition
(EMT) process as a key cellular mechanism in tumorigen-
esis, as well as the important discovery that stem cells of
mesenchymal origin (mesenchymal stem cells (MSC)) can
home towards tumor sites. The latter has formed the basis
of an exciting new anti-cancer strategy, namely cancer
cytotherapy, in which allogeneic MSC can be used to spe-
cifically target and deregulate the local tumor microenvir-
onment, as an answer to modern oncology’s desperate need
for a promising alternative to the current gold-standard
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therapy of combined chemotherapy (Additional file 1:
Figure S1).
Towards this end, various MSC populations have been
recruited in different experimental setups in dozens of in
vitro and in vivo preclinical studies. Unfortunately, until re-
cently, MSC-based cancer cytotherapy has to a large extent
failed to deliver its initial promise of a high-end transla-
tional oncology option. In their vast majority, the 500 or
more clinical trials employing the use of MSC take advan-
tage of the immunomodulatory, anti-inflammatory, and tis-
sue regenerative properties of these cells for treating, for
example, autoimmune diseases, graft rejection and osteo-
chondral degeneration, without, until very recently, any sig-
nificant data on the anti-cancer efficacy of MSC in humans.
The problem of translating experimental MSC-based can-
cer cytotherapy work into successful human clinical trials is
multi-faceted. In the case where MSC are engineered to
overexpress molecules with anti-cancer properties, tumor
suppression is achieved with relatively high efficiency and
reproducibility in the majority of experimental protocols
applied. Nevertheless, genetic engineering of cells not only
adds extra costly and time-consuming manipulation steps
in vitro, but also raises safety concerns since it usually relies
on the use of viral vectors that introduce instability and
chances of mutation at the genome integration sites of the
host. On the other hand, the use of naïve, unmodified stem
cells, although more straightforward, is hampered by
contradictory findings, largely driven by the immense bio-
logical variability inherent to cell-based products and ther-
apies (compared to traditional pharmaceuticals), as well as
by multi-parameter variability relating to the methods, pro-
cesses and manipulation steps mediating transformation of
lab findings to clinical-grade products.
With a mortality rate of nearly 60% for the over 14
million people diagnosed with cancer yearly world-
wide, it is imperative that any novel therapeutic re-
gime should be optimized to its full potential.
Obviously, experimental cancer cytotherapy is at a
nodal point, where the critical mass of information
accumulated by the series of studies performed over
the last two decades needs to be thoroughly revised,
carefully analyzed, and properly evaluated in the con-
text of immunobiology of the tumor microenviron-
ment. With the first-in-human clinical trials assessing
genetically modified MSC in gastrointestinal and lung
cancer settings only very recently and more to follow,
this task has become an essential one more than ever
before [1]. More specifically, in order for the field to
move forward, any new experimental attempt should
be built upon (a) a clear understanding of the interac-
tions between components of the local tumor envir-
onment during its progression from benign stromal
tissue to a niche tuned to support growth, invasion,
and metastasis of malignant cells and (b) careful
experimental design that minimizes unnecessary du-
plication of work as well as the emergence of tech-
nical heterogeneity.
With all the above in mind, we present here a system-
atic review of the advances in the MSC-based cancer
cytotherapy field from its inception onwards, including
the state-of-the art of the biology and relationship be-
tween the effectors (MSC populations) and targets
(tumor niche components) implicated (discussed in the
section “MSC and the tumor microenvironment—attri-
butes and inter-relationship in the context of cancer
cytotherapy”). Amalgamated in this review is a
meta-analysis of the related bibliography, which was
carefully designed and implemented in such a way to
allow the extraction and decoding of the overwhelming
number of experimental data presented therein and,
hence enable the identification of commonalities and dif-
ferences between studies, the dissection of emerging
trends and patterns in reported findings, and possibly
highlight any significant omissions or weaknesses in ex-
perimental design (presented in the “Methodology of the
meta-analysis” and “Overview and discussion of the
meta-analysis’ main findings” sections). Finally, in the
concluding part (“Conclusions” section) of this review,
an effort is made to both present the main findings as
concise summary points in the context of state-of-th-
e-art knowledge, which potentially can serve as a guide
map, aiding the adoption of optimal conditions for the
development of more efficient, translational cytotherapy
protocols with extended clinical relevance.
MSC and the tumor microenvironment—attributes
and inter-relationship in the context of cancer
cytotherapy
The composition and dynamics of the tumor stromal
microenvironment and the role of EMT in tumor
development
Cells within the tumor parenchyma are not self-sustain-
ing entities, but develop in a symbiotic manner by inter-
acting via paracrine and juxtacrine signaling with the
surrounding stroma. The stromal microenvironment is
the non-neoplastic compartment of tumors and com-
prises a dynamic and highly heterogeneous network of
tumor vasculature (including pericytes), infiltrating in-
flammatory and immune cells, extracellular matrix
(ECM), (myo) fibroblastic cells (also known as tumor-as-
sociated fibroblasts (TAFs)), mesenchymal stromal/stem
cells, and sometimes adipocytes [2], as well as reactive
stroma [3]. Most if not all solid tumors have some de-
gree of tumor stroma, and the presence of reactive
stroma is often an indicator of poor prognosis [4]. Com-
munication between cellular components of the tumor
microenvironment is achieved through cytokines, che-
mokines, growth factors, and inflammatory and matrix
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remodeling enzymes that contribute to the malignant
properties of the cells.
Among the immune cells that infiltrate the tumor
stroma and are present within the tumor microenviron-
ment, selective T and B lymphocyte populations favor or
suppress tumor growth and their detection has been as-
sociated with subsequent clinical outcomes [5–7].
Tumor-associated macrophages (TAM) and neutrophils
(TAN) are usually pro-tumorigenic. TAMs participate
actively in metastasis, being thus implicated in poor
prognosis [8], while TANs enhance angiogenesis and im-
mune suppression [9, 10].
Perivascular stromal cells, known as pericytes, are an-
other essential component of the tumor stroma that se-
cures vasculature maintenance by providing structural
support to blood vessels [11]. Although pericytes are
present within normal blood vessels, tumor vessels are
characterized by excess pericyte coverage that contrib-
utes to their abnormal physiology.
Fibroblastic stromal cells within the tumor stroma,
known as TAFs, have been linked to several processes
that promote cancer metastasis and growth, including
angiogenesis [12], EMT [13], and progressive genetic in-
stability [14, 15]. TAFs exert their tumor-promoting ac-
tions through secretion of growth factors, cytokines,
chemokines, structural protein components, and metab-
olites that act upon tumor cells [2]. Additionally, fibro-
blastic stromal cells can deregulate antitumor immune
responses, as exemplified by experiments demonstrating
that allogeneic murine tumor cells, when co-injected
with fibroblastic stromal cells, can engraft across im-
munologic barriers [16]. Together, these studies suggest
that tissue-specific fibroblasts are influential players in
the progression of metastatic cancer and, at first glance,
appear to benefit tumor growth and decrease overall pa-
tient survival. However, there is mounting experimental
evidence that healthy tumor microenvironments sup-
press tumor growth, and it is only after acquisition of
tumor-like genetic lesions that fibroblasts appear to pro-
mote tumor progression [14, 17, 18].
ECM is another key regulator of tumor development
and progression by providing both a structural scaffold
for the tumor stroma and also active soluble factors in-
cluding growth and angiogenic factors, cytokines, and
chemokines that regulate tumor behavior. During tumor
development, the ECM is usually disorganized and colla-
gen deposition as well as cross-linking with other matrix
proteins such as elastins, laminins, or fibronectin has
been associated with cancer invasion and metastasis
[19]. Among the ECM-secreted growth factors, TGF-β is
known to promote EMT in cancer cells, thus increasing
local and distant invasive potential [20].
ΕΜΤ is the process by which epithelial cells reduce
the expression or function of proteins that promote
cell-cell and cell-basement-membrane adhesion and thus
obtain a mesenchymal-like phenotype. Except for the
regulation of metastatic properties, the EMT has been
also associated with acquired drug resistance [21]. Fur-
thermore, high expression of EMT-induced markers
(vimentin, α-smooth muscle actin (a-SMA), N-cadherin,
cadherin 11, SpArC, laminin and fascin) with simultan-
eous low expression of E-cadherin has been associated
with poor prognosis in patients with breast cancer [22].
Principal common characteristics of isolated human MSC
populations used in cytotherapy protocols
Stem cells possess a unique capacity of self-renewal, differ-
entiation into multiple cell types and in vivo tissue repopu-
lation [23]. These functions are triggered by signals that
impel a stem cell to undergo either symmetric or asymmet-
ric divisions [24]. Based on their ability to give rise to one
or more different cell lineages, stem cells are characterized
as totipotent (able to give rise to all cells constituting the
developing embryo), pluripotent (e.g., isolated embryonic
stem cells (ESC) that can differentiate into cells of all three
germ layers), multipotent (capacity for differentiation to-
wards most cell lineages), and unipotent (mono-specific dif-
ferentiation). Mesenchymal stem cells (MSC) are
multipotent stem cells that upon stimulation give rise to
most body cell types including those of muscle, bone, fat,
and cartilage lineages [25]. MSC were originally isolated
from bone marrow (BM) aspirates; nevertheless, they can
be isolated from many types of adult and fetal tissues using
similar methodologies [26]. Adipose tissue (AT) provides a
particularly abundant and accessible source, although many
other adult tissue sites can also be utilized including kidney,
skin, and the parathyroid gland [27]. In another study, it
has also been suggested that a small population of MSC cir-
culates within the peripheral blood and is highly mobilized
during hypoxia [28]. MSC or MSC-like cells have been iso-
lated from fetal tissues as well, including skin, cord blood
(-CB), umbilical cord (-UC), and placenta [29]. Regardless
of their origin, these MSC share similar defining character-
istics including plastic adherence, cell surface marker ex-
pression (negative for hematopoietic markers CD34, CD35/
positive for core markers CD29, CD44, CD73, CD90,
CD105), and at least a tri-lineage differentiation potential
(towards fat, bone, cartilage) under certain conditions [26].
The native functions are thought to include wound healing
and support of hematopoiesis. More interestingly, when
engrafted at sites of injury, MSC differentiate into connect-
ive tissue elements, support vasculogenesis, and secrete cy-
tokines and growth factors that facilitate healing and tissue
regeneration. In addition, due to their complex immuno-
modulatory properties, MSC can counteract inflammation,
suppress host immune responses, and prevent fibrosis [30].
As a consequence of their diverse properties, MSC have
been extensively utilized in the last decade in therapeutic
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applications such as tissue repair and regeneration, as well
as autoimmune disease [31]. For example, the immunosup-
pressive effects of MSC have been used for therapy of
graft-vs.-host disease (first MSC biologic drug).
Another common feature of MSC is that they are able
to localize to sites of hematopoiesis, inflammation, or in-
jury as well as to solid tumors, by a mechanism charac-
terized as homing. Tumor tropism distinguishes MSC
from other mesenchymal cells, such as differentiated fi-
broblasts [32]. This homing ability of MSC to injured
sites and their interaction with the local microenviron-
ment has encouraged investigation into the possibility of
using these cells, either unmodified or as gene or even
drug delivery vehicles for targeted cytotherapy, most
notably cancer treatment [33, 34]. Interestingly, it has
also been shown that co-injection of MSC promotes
growth of various tumors in vivo, possibly due to the
immunosuppressive effects that help cancer cells escape
immunosurveillance [16, 35].
Tumor tropism of MSC and the dynamic inter-
action between MSC and the tumor microenviron-
ment, due to their complexity as well as their
significance for cancer therapy, require a deeper un-
derstanding and merit further investigation and hence
are discussed in more detail in the following sections
of this review.
The tropism of MSC homing to tumors as the basis of
cancer cytotherapy
Homing is the process by which cells migrate to, and en-
graft in, the tissue in which they can exert local functional
effects. It is well established that MSC are recruited to sites
of injury to support tissue repair, stem cell homeostasis,
and immunomodulation. Tumors can be considered as
chronic wounds and, thus, attract MSC in similar ways as
injured tissues [36]. The homing ability of MSC towards tu-
mors has been verified and studied in animal models in a
variety of experimental settings, and it has been shown that
MSC are active regulators of tumor progression [37, 38].
Homing and migration of MSC to tumor sites has been
proved to be mediated by monocyte chemotactic protein-1
(MCP-1 or CCL2) secreted by primary breast cancers [39],
or stromal cell-derived factor 1 (SDF-1), a small chemotac-
tic cytokine that activates leukocytes and is often induced
by proinflammatory stimuli such as TNF-α or IL-1 [40] in
response to prostate, colorectal, and breast cancer in vitro
[41]. On the other hand, in cases of malignant gliomas,
MSC recruitment is achieved through interaction with a
large array of angiogenesis-related cytokines including IL-8,
TGF-β, and VEGF secreted by cancer cells [42]. Moreover,
a component of the extracellular matrix, matrix metallopro-
teinase 1 (MMP-1) stimulates MSC homing through
cleavage and subsequent activation of the G-protein
protease-activated receptor (PAR)-1 [43] (Fig. 1).
It is believed that the mechanisms orchestrating MSC
homing to sites of injury, and consequently to tumors, re-
semble the migration of leukocytes towards sites of injury
and inflammation, which is well studied. It has been dem-
onstrated that bone marrow stroma-derived MSC
(BM-MSC) express high levels of adhesion molecules, in-
cluding integrins β1 and a4, which can mediate the en-
graftment of MSC to the bone marrow [44, 45]. The α4/
β1-VCAM-1 interaction has a central role in MSC com-
munication with endothelial cells [46]. In the same con-
text, the interaction between a4/β1 on MSC and its
binding site on fibronectin of the ECM has been reported
to play a major role in transmigration of MSC into the
extracellular matrix [47] (Fig. 1). Other mechanisms con-
tributing to the homing ability of MSC include P-selectin,
MMP-2 secretion, and a number of cytokines [46].
Once in the tumor, attracted MSC interact with the
tumor microenvironment leading to its remodeling and
promoting cancer progression. It has been reported that
MSC that home to tumor sites are transformed into TAFs
[2] and promote tumor angiogenesis and invasive proper-
ties [48]. MSC interact with tumor cells in myriads of
ways and modulate their behavior. Interactions between
tumor cells and tumor-associated MSC are highly plastic
and bidirectional. The activity of MSC within the tumor
stroma includes enhanced secretion of TGF-β that con-
tributes to the EMT process and immune-suppressive ac-
tivities. Moreover, they release VEGF, which contributes to
neovascularization within the tumor microenvironment
and they also produce SDF-1 to support tumor cell
growth and survival [2]. MSC also secrete CC-chemokine
ligand 5 (CCL5), also known as RANTES, which interacts
with specific cytokine receptors such as CCR1, CCR3, or
CCR5. CCL5 paracrine signaling was found to promote
the migratory, invasive, and metastatic properties of breast
cancer cells [49].
Another way of communication between MSC and
cancer cells includes the exchange of microparticles, like
exosomes. MSC-derived exosomes can modulate the
function of tumor cells through induction of MMP-2
and ecto-5′-nucleotidase activity, thus enhancing the
heterogeneity within the tumor microenvironment [50],
while they also enclose tumor supportive micro RNAs,
which enhance tumor growth [51]. Simultaneously, can-
cer cells secrete exosomes that stimulate BM-MSC to
differentiate into pro-angiogenic myofibroblasts with
tumor-promoting properties [52]. Nevertheless, in many
cases, MSC have been shown to exhibit tumoricidal be-
havior within tumors, as it will be discussed below.
The tumor microenvironment is a highly dynamic, plas-
tic, and heterogeneous welter of cells and cellular factors
that provide support and protection to the developing
tumor and thus its therapeutic targeting constitutes a
popular anti-cancer approach [13, 53]. The ability of MSC
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to home to and interact with tumors is being exploited for
the effective targeting of the tumor microenvironment
[54, 55].
Divergent outcomes of MSC-based strategies for cancer
cytotherapy
The unique homing property of MSC has been exploited
in cancer cytotherapy protocols using various MSC pop-
ulations (mainly of adult origin), either naïve or engi-
neered to carry genes with antitumorigenic properties.
But whilst genetically modified adult MSC have shown
good efficacy in ex vivo and animal cancer models, naïve
cells, on the contrary, have produced largely conflicting
results by either promoting or suppressing tumor devel-
opment. For a long period of time, mainly between 2000
and 2006, the research involving MSC-based cancer
cytotherapy was limited only in the use of BM-MSC,
with, in most cases, lack of encouraging results [56–58].
On the contrary, though, in an in vivo study by Khakoo
et al., intravenously administered BM-MSC homed to
tumorigenic regions and dynamically suppressed tumor
growth in a mouse model of Kaposi’s sarcoma [59]. Since
then, an increasing number of studies have come up
with rather contradictory results regarding the use of
MSC for experimental cancer treatment. Such conflict-
ing (pro- vs. antitumorigenic) results have been recorded
both in vitro and in vivo, for various cancer types in
some cases even for the same cancer cell line. In support
of these observations, the use of BM-MSC against colon
cancer cell lines has either led to promotion of the
tumorigenic properties of these MSC [60] positively af-
fecting proliferation of cancer cells, or, on the contrary,
was cytotoxic for the latter [57]. Furthermore, an
onco-suppressive effect could not be established in vivo
either, since human fetal or adult-derived BM-MSC were
found to promote tumor growth, following their sub-
cutaneous co-injection with SW480 colon cancer cells,
in BALB/c-nu/nu mice [61]. Bone marrow-derived MSC
are, though, not the only stem cells that show this erratic
behavior. Due to the relatively greater ease and efficiency
of isolation, adipose tissue-derived MSC (AT-MSC) have
also been recruited for the development of experimental
cancer cytotherapy protocols. Similarly to BM-MSC,
AT-MSC have been shown both to promote and inhibit
the survival of brain [62–64], breast [65], and prostate
[66, 67] cancers in vitro and in vivo. The number of
Fig. 1 Mechanisms of MSC homing to tumor sites. Binding of monocyte chemotactic protein-1 (MCP-1 or CCL2), secreted by breast cancer cells
or of stromal cell-derived factor 1 (SDF-1) secreted by breast, colon, and prostate cancer cells, on their receptors expressed on MSC surface can
modulate the tropism of MSC to tumor sites. Matrix metalloproteinase 1 (MMP-1), localized in the extracellular matrix (ECM), stimulates MSC
homing through cleavage and subsequent activation of the G-protein protease-activated receptor (PAR)-1. In correspondence with the homing
process of MSC to sites of injury, the interaction between integrin α4/β1 on MSC and its binding site on fibronectin of the ECM plays a major
role in the transmigration of MSC into the extracellular matrix. Finally, MSC recruitment can also be achieved through interaction of VEGF,
secreted by cancer cells, with its receptor on MSC. After incorporating in tumor site, MSC in turn secrete various pro-angiogenic factors, such as
VEGF, fibroblast-derived growth factor, PDGF, and SDF-1 that facilitate angiogenesis
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reports implicating umbilical cord matrix-derived MSC
(UC-MSC) in conflicting cytotherapy outcomes is, so far,
scarce and limited to in vitro experimentation. For ex-
ample, a study by Li et al. [68], reporting the promotion
of proliferation and metastasis of MDA-MB-231 and
MCF-7 breast cancer cells in vitro, is outweighed by a
series of studies showcasing the opposite effect on the
two cell lines in vitro and in vivo [69–73].
Besides conflicting results observed within specific
MSC (effector) and tumor (target) combinations, contra-
dictory findings have also been obtained with regard to
the effect of different MSC populations on the same
tumor target, strongly suggesting a close association be-
tween the antitumorigenic properties of the former and
their developmental origin. With respect to breast can-
cer, for example, a great number of studies (mainly in
vitro) have quite convincingly showed a robust
tumor-promoting effect of both BM-MSC [49, 56, 58,
74–78] and AT-MSC [62, 65, 79, 80] on at least two dif-
ferent breast cancer cell lines. On the other hand, an
equally large group of studies using UC-MSC clearly
demonstrate the opposite (onco-suppressive effect) on
the same cell lines both in vitro and in vivo, as stated
previously [69–73].
Finally, apart from the cases where the dubious effi-
cacy of certain MSC against some tumors arises from
contrasting reports in the literature, there are also cases
where questions are raised over the therapeutic value of
those naïve MSC that have been shown to possess strong
onco-suppressive characteristics, albeit by yet uncon-
firmed reports. Such examples are the cases of AT-MSC
vs. pancreatic cancer [66], BM-MSC vs. non-Hodgkin’s
lymphoma [81] and UC-MSC vs. prostate [82] and blad-
der tumors [83].
Clearly, more focused work will lead to data accumula-
tion, analysis of which will help in identifying trends and
will fill in knowledge gaps regarding effectiveness of ex-
perimental cancer cytotherapy, at the same time shedding
more light on the underlying biological mechanisms.
In the following sections, we discuss some of these
mechanisms that may attribute to the complexity and
adversity of experimental cancer cytotherapy outcomes
and next present our meta-analysis strategy for decoding
all available data from the field at its current state of
maturity.
Possible mechanisms mediating the bimodal effects of
exogenous MSC on tumors
Once MSC migrate to the sites of tumor development, they
interact with components of the neoplastic parenchyma as
well as with supportive stroma. The exact dynamics of this
crosstalk is dependent on the developmental stage and ori-
gin of the MSC as well as the type and site of tumor tar-
geted. Nevertheless, the final outcome, tumor support or
suppression, is most likely determined by the resulting tilt
in balance between the respective mediating mechanisms
(reviewed in [84]). In the first case, instrumental processes
for MSC are the promotion of angiogenesis and contribu-
tion to the fibrovascular stromal network, mitigation of im-
mune reactions, and stimulation of EMT and metastatic
processes, while in the case where MSC exert a suppressive
effect on the developing tumor, mechanisms such as cancer
cell control, apoptosis induction, and regulation of Wnt
and AKT signaling are involved and dominate.
Support of tumor vasculature and fibrovascular network
Α significant amount of in vivo experimental data, in-
cluding labeled MSC tracking, support the contribution
of MSC to the tumor vascular and fibrovascular net-
work, either directly by differentiating into pericytes, fi-
broblasts, and myofibrobasts that transform into TAFs
[35, 85] or indirectly through secretion of specific
growth factors [86]. A MSC-like population expressing
the characteristic surface markers CD10, CD13, and
CD90 has been identified within pericytes isolated from
the stromal-vascular compartment [87, 88].
Once in the tumor microenvironment, MSC acquire
expression of TAF antigens, such as a-smooth muscle
actin (a-SMA), fibroblast-specific protein, vimentin, and
SDF-1 in vivo and in vitro following co-culture with
tumor cells or using tumor-conditioned media [35, 89].
In accordance with this data, human BM-MSC have
been found to promote angiogenesis and tumor blood
vessel reorganization in a murine mammary adenocar-
cinoma model, with increased a-SMA expression, when
hMSC were injected in the tumor periphery or intraven-
ously [90]. In another orthotopic mouse model of colon
cancer, co-injected MSC were incorporated into the
tumor stroma and expressed a-SMA, PDGFRb, desmin,
FSP, and FAP as TAF markers [91]. However, when
hAT-MSC were co-injected with U87MG and H460
brain tumor cells in BALB/c nude mice, no vascular sup-
port was observed [63].
MSC also secrete various pro-angiogenic factors, such
as VEGF, fibroblast-derived growth factor, PDGF, and
stromal-derived factor-1 (SDF-1), that facilitate angio-
genesis through promotion of endothelial and smooth
muscle migration and proliferation towards the tumor
site [92]. MSC-expressing VEGF caused increased
microvessel density in pancreatic xenografts [93] and en-
hanced neovascularization in syngeneic mouse models
of melanoma and lung tumors [94]. However, VEGF is
not the basic factor that promotes angiogenesis and
other pro-angiogenic cytokines must be involved in
tumor vasculature expansion by MSC, as recombinant
VEGF did not have the same effect on vessel growth as
did the MSC-conditioned media [92]. VEGF, IL-8, angio-
genin, and CCL2 were significantly enhanced by the
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concomitant presence of MSC and lymphoma cells in
C.B-17 severe combined immunodeficiency (SCID) mice,
contributing to the migration of endothelial cells in
transwell assays. However, when MSC were directly
co-cultured with endothelial cells, a significant induction
of endothelial cell apoptosis was recorded [81]. Other
MSC-secreted growth factors implicated on tumor vas-
culature facilitation include hepatocyte growth factor, cy-
clooxygenase, IGF-1, PDGF-a, and transforming growth
factor-a1 [93]. Finally, it has been proposed that gastric
cancer exosomes can trigger differentiation of UC-MSC
to carcinoma-associated fibroblasts and thus enhance
the tumor fibrovascular network, an effect that can be
eliminated through blockade of the TGF-β pathway [95].
On the other hand, a number of studies support the
involvement of MSC in suppression of the tumor angio-
genic network. MSC were found to migrate towards and
inhibit growth of endothelial cell-derived capillaries in
vitro through production of reactive oxygen species. The
growth-suppressing effect of MSC was also observed in
vivo, where established melanoma tumors injected with
MSC exhibited lower vascular density [96].
Immunomodulatory effects on tumors
MSC are thought to promote tumorigenesis through
their immunomodulatory behavior, which is character-
ized mainly by immunosuppressive effects that can be
beneficial for cancer cells to escape the immune system
surveillance [97]. MSC act directly on immune cells, in-
cluding B and T lymphocytes, dendritic cells, and nat-
ural killer cells [97–99]. MSC can suppress T cell activity
by either inhibiting their proliferation or, in case of acti-
vated T lymphocytes, by leading them to apoptosis [100,
101]. Inhibition of T cell proliferation has been found
enhanced by different mechanisms, like interferon
(IFN)-gamma-mediated upregulation of an inhibitory
cell surface marker, B7-H1 [102], or by Stro-1 expression
[103]. In addition, Toll-like receptor (TLR) signaling has
also been shown to contribute to the immunomodula-
tory properties of MSC, as expression of certain recep-
tors can lead MSC to switch from a predominately
immune-suppressive to a proinflammatory phenotype
[104]. On the other hand, Puissant et al. showed that
both AT-MSC and BM-MSC can inhibit lymphocytes
only when they are in close contact [105], while in an-
other study, UC-MSC (isolated from Wharton’s Jelly
(WJ)-MSC) were able to suppress proliferation of per-
ipheral blood lymphocytes [106].
The in vivo immunomodulatory effects of MSC are
still poorly studied within tumors. In a study by Djouad
et al., the reported immunosuppressive action of MSC
led to a higher incidence of melanoma formation in an
allogeneic mouse model [16]. Based on the immunosup-
pressive properties of MSC, these cells have been
proposed to suppress the graft-vs.-leukemia effect and
the graft-vs.-host response [107, 108].
Pro-metastatic effects and stimulation of EMT
The contribution of MSC to the establishment of distant
metastases is rather controversial, ranging from promotion
to suppression in a number of studies. For example, intra-
venous injection of MSCs derived from umbilical cord
blood or adipose tissue reduced the formation of lung me-
tastases in mice with established mammary tumors [109].
In contrast, mice that received subcutaneous co-injections
of human breast cancer cells with human BM-MSC dis-
played a marked increase in the numbers of micro- and
macroscopic lung metastases. The pro-metastatic effect of
MSC was found mediated through paracrine action, by the
secretion of chemokine CCL5 from MSC in two out of four
cell lines tested, as the metastatic potential was abolished
when CCL5 expression was eliminated [49]. In a 3D model
of hepatocellular carcinoma, co-culture with UC-MSC led
to increased secretion of MMP2, which in turn enhanced
the invasive ability of cancer cells [110]. Additionally,
hBM-MSC secrete IL-17B, which may act through
IL-17BR—a prognostic indicator of breast cancer progres-
sion and metastasis—to stimulate metastasis. This hypoth-
esis was tested in a humanized model of breast cancer
metastasis to bone, where co-injection of cancer cells with
BM-MSC increased the frequency of metastases with in-
creased expression of IL-17BR [75].
MSC may also modulate EMT, a developmental
process that is subverted by tumor cells, resulting in a
more invasive phenotype. Co-culture of breast cancer
cells with MSC resulted in upregulation of EMT-specific
markers (N-cadherin, vimentin, Twist, and Snail) and a
decrease in E-cadherin [111]. Another mechanism of
MSC-mediated promotion of metastasis includes the for-
mation of early metastasis through vasculogenesis or
growth factor secretion. Accordingly, MSC facilitated
the entry of breast cancer cells into the bone marrow
through Tac-1 regulation of SDF-a1 and C-X-C chemo-
kine receptor type 4 (CXCR4) [112]. In support of this
observation, Zhang et al. showed that MSC from the
bone marrow can promote pulmonary metastasis of
osteosarcoma tumors in mice, through a mechanism in-
volving the CXCR4/VEGF axis [113].
Regulation of signaling pathways
In many cases, the tumoricidal action of MSC on tumors
has been associated with suppressive effects on signaling
pathways crucial for cancer progression, proliferation,
and survival, mainly involving the PI3K/AKT and Wnt
pathways. Inhibition of AKT was reported in a Kaposi’s
sarcoma model, where intravenously injected MSC mi-
grated to tumors and effectively inhibited tumor prolifer-
ation [59]. MSC can also suppress the WNT/β-catenin
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pathway through induced expression and secretion of
DKK-1 in human carcinoma cell lines. Interestingly,
when DKK-1 was inhibited, tumor cell proliferation was
restored [114, 115]. The ERK/MAPK signaling pathway
has also been implicated in tumor promotion by MSC,
since drug-mediated inhibition of ERK in breast cancer
cells cultured in MSC-CM resulted in decreased prolifer-
ation of tumor cells [68].
Many studies have concentrated on the anti-cancer
functions of neonatal MSC, highlighting the primitive
characteristics that render them non-tumorigenic.
Among these, WJ-MSC show modest expression of plur-
ipotency genes and high levels of several tumor suppres-
sor genes, while they secrete a variety of growth factors
and cytokines that inhibit tumor growth [70, 116, 117].
Regulation of cell cycle and apoptosis
Studies investigating the effects of MSC on tumors have
shown that they either promote or inhibit apoptosis, lead-
ing to tumor attenuation or progression, respectively. Inter-
actions between MSC and cancer cells in the bone marrow
have been shown to promote survival of acute myelogenous
leukemia through upregulation of anti-apoptotic bcl-2 with
reduced rates of apoptosis in response to cytotoxic chemo-
therapy [118]. Furthermore, culture of colorectal cancer
cells in the conditioned medium (CM) of MSC downregu-
lated the expression of the apoptosis-related proteins Bax
and p53 and upregulated the anti-apoptotic protein Bcl-2,
leading to inhibition of apoptosis, while under the same
conditions cancer cell cycle was promoted with an in-
creased percentage of cells found in the S phase [60]. Ex-
cept for promoting anti-apoptotic events, MSC have been
reported to protect osteosarcoma cells from drug-induced
apoptosis, through activation of the STAT3 pathway [119].
On the other hand, Lu et al. demonstrated that MSC
had an inhibitory effect on mouse tumor cells and asci-
togenic hepatoma cells in a cell-dependent manner in-
volving Caspase 3, an apoptotic protein, and p21, a
negative regulator of cell cycle, implying that MSC exert
tumor inhibitory effects in the absence of host immuno-
suppression, by inducing G0/G1 phase arrest and apop-
tosis of cancer cells [120]. G1 phase arrest was also
observed when leukemia cells were cultivated with MSC
in vitro [34]. Similar results were obtained after intratu-
moral administration of MSC into melanoma-bearing
mice, where interaction of MSC with the neocapillary
network in the tumors caused cytotoxicity and apoptosis
of the tumor-associated endothelial cells [96].
MSC-based cancer cytotherapy—current challenges and
gaps of knowledge
Unquestionably over the last quarter of the century, the
explosion of research in molecular cell biology and
immunobiology of stem cells and cancer have shed light
on the composition and establishment of the tumor
microenvironment, on mechanisms governing MSC
homing to tumor sites and interaction with components
therein, as well as on signaling cascades and molecular
events mediating the pro- or antitumorigenic effects. In
its majority, this bulk of knowledge has stemmed from
applied work using MSC in variety of in vitro/in vivo
tumor models. However, the complexity of the field and
the heterogeneity and diversity of the outcomes have in-
evitably led to new elementary questions that remain to
be resolved. Some of these are: Have research work ef-
forts so far been correctly prioritized or have they been
prone to partiality and duplication? What are the crucial
areas that we may need to focus on both experimentally
and conceptually in order to maximize clinical rele-
vance/impact? To what extent is the discrepancy in re-
sults attributed to technical rather than biological
heterogeneity? What are the mechanisms mediating
anti-cancer efficacy in different MSC populations? Can
we improve consistency and efficiency of primary out-
come by optimization of experimental parameters? Is
there an MSC type/source bearing “universally” consist-
ent tumor suppressive action against a wider range of
tumor targets and with fewer adverse effects in compari-
son to others? If so, what are the properties that give it
an advantage, are they uniquely inherent, or can they be
mimicked by specific experimental interventions/adapta-
tions? Are there some MSC/tumor combinations which
decisively give better results than others in experimental
research work and should therefore be given priority in
clinical trials? To what extent does genetic modification
of MSC ameliorate the anti-cancer behavior of naïve
MSC? Are specific genetic modification methodologies
applied on MSC effector cells more efficient than others
against tumor targets? Given the uncertainty of naïve
MSC-based tumor cytotherapy and on the other hand
the more robust performance of genetically modified
MSC, should bench research and clinical trials focus pri-
marily on the latter?
In the following sections of this review, we present a
strategy for identifying the sources of heterogeneity, for
evaluating their relative impact on cytotherapy outcome,
and we summarize trends and patterns ultimately using
our findings to address the aforementioned issues.
Methodology of the meta-analysis
Until this day, several reviews have focused on summar-
izing the aforementioned conflicting results involving
the efficacy of MSC in cancer treatment and have, in
some cases and to a limited extent, tried to dissect the
causal relationship to those discrepancies [84, 121]. The
novelty of this review lies in the specific strategy that we
adopted for extracting, recording, and organizing experi-
mental parameters, sourced from selected publications
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in order to, first, investigate associations and patterns
concerning reported discrepancies and, second, highlight
the optimal conditions for the development of more effi-
cient and reliable protocols for naïve MSC-based cancer
cytotherapy.
As part of this effort to elucidate the conditions and fac-
tors that could possibly affect the behavior of MSC against
tumors, we conducted a small-scale meta-analysis based
on information extracted from the literature using a
four-step strategy: (1) compilation of a relevant publica-
tion library, (2) deconstruction of literature methodology
and reported findings, (3) classification and organization
of extracted experimental data, and (4) data consolidation
and statistical analysis (Additional file 2: Figure S2). In the
first stage, the PubMed online bibliographic database was
queried for the combinations of keywords “x AND y AND
z” (where “x” was “adipose stem cell” or “bone marrow
stem cell” or “umbilical cord stem cell” or “Wharton jelly
stem cell”, “y” was “mesenchymal”, and “z” was “cancer
therapy” or “cancer treatment”), using the following lim-
iters: Humans, English, Journal article, and published from
year 2000 onwards. The reference lists generated from the
above searches were merged (replicates removed) into a
single reference library comprising a total of 861 unique
articles, using Endnote X2 citation manager software
(Thomson Corp.). The list was then carefully examined
manually for specific relevance to experimental cancer
cytotherapy studies employing the use of human
post-natal stem cells of non-hematopoietic origin, on hu-
man tumor cell lines or primary tumor cells. This resulted
in a nearly 10-fold compacted library of 108 highly rele-
vant publications whose reported findings formed the
basis of our meta-analysis. In the second step, the articles
were initially divided into two categories: (a) referring to
studies using only unmodified (naïve) human MSC
(n-MSC; n = 55) and (b) relevant to experimental
cytotherapy models utilizing genetically modified human
MSC (GM-MSC; n = 53). Subsequently, detailed informa-
tion available in the methodology and results sections of
the manuscripts were extracted and recorded in spread-
sheets using Microsoft Excel. Strings of information were
classified into five broad categories, namely type of stem
cells used (effectors) and type of their tumor target (tissue/
cell lines), characteristics of effector-target interface (e.g.,
dosing, route/timing/method of administration, culture
format/animal model adopted), methodology applied for
cell modification/labeling and endpoint analyses/assays,
and key findings and primary outcome (i.e., pro-/antitu-
morigenic effect), thus populating a preliminary descrip-
tive database. In the following step, this compartment
alized information was further fragmented and reassigned
into over 20 categories (fields) designated “experimental
parameters” (see field titles of Additional file 3: Figure S3)
to construct a detailed database using Microsoft Access
2010. In this third step, data stratification (expansion of
number of categories/fields with simultaneous simplifica-
tion of field contents) allowed us to recognize individual
effector-target combinations with matched primary out-
comes, termed “experiments.” More than one such experi-
ments per article were reported in some cases, leading to
the identification of a total of 156 experiments, which
were allocated in three distinct groups: (1) experiments
describing the effect of unmodified (naïve) MSC (n = 89),
belonging to the first category of articles above, (2) experi-
ments of the second article category which refer to the
use of naïve MSC as controls for evaluating GM-MSC
anti-cancer efficacy (n = 43), (3) experiments (again in-
cluded in the second article category) that describe the
anti-cancer efficacy of GM-MSC without a direct com-
parison with naïve MSC (n = 24). The primary outcomes
of these experiments were flagged as tumor promotion or
suppression (or neutral, if no significant difference was ob-
served between treatment and relevant controls) depend-
ing on the results of the in vitro/in vivo assays as
described in the respective publications. In the final step,
the experimental parameters were used to derive database
queries and to perform statistical analyses, the outcome of
which is discussed in the following section.
Overview and discussion of the meta-analysis’
main findings
Naïve MSC-based cancer cytotherapy: from trend
identification to protocol optimization
Relevance of preclinical cancer cytotherapy targeting to
global cancer incidence
Statistical analysis of the experimental data extracted
from the literature has highlighted eight types of tumors
as most frequently targeted in naïve MSC-based cancer
cytotherapy experimental protocols (Fig. 2). In an effort
to put these tumors into clinical context, they were com-
pared to global incidence [122]. Interestingly, the list of
the 10 most frequently targeted tumors has a corre-
sponding total incidence of just over 60% globally; the
remaining 40% includes important cancers (cervical,
esophageal, bladder, N-H lymphoma) which conclude
the top 10 global cancer incidence list, but nevertheless
are not the main focus of experimental cytotherapy ef-
forts. Moreover, a more thorough comparison of the
data revealed a predisposition of the use of naïve MSC
towards specific cancer types, as well as a notable in-
verse relationship between the frequency of cancer tar-
gets used in MSC-based cytotherapy experiments and
the cancer types with the highest clinical incidence and
mortality worldwide. Thus, while breast cancer with fre-
quencies of 30% is the most popular target and is
over-represented in comparison to its global incidence
(19.6%), lung cancer, on the other hand, which is the
most frequent and one of the most lethal types of cancer
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worldwide, is greatly under-represented in in vitro/in vivo
experimentation (7.1% vs. an incidence of 21.4%). Actually,
in cancer epidemiology, nearly one in two cancers are lung
or hepato-gastro-pancreatic (HGP) cancers with a
top-ranking, combined mortality rate of nearly 90%, yet
they comprise less than 25% of cytotherapy targets. It is
worth noting that HGP tumors are the only type featuring
in the top three most frequently targeted by all three MSC
types in cytotherapy studies, albeit with a frequency less
than half than they affect patients globally (Fig. 2). Even
more impressive is the under-representation of prostate
cancer (the second most frequent cancer in adult male
population), as well as the absence of studies regarding
the use of UC-derived MSC on colorectal cancer. On the
opposite side, we have the over-representation of brain tu-
mors (glioma/glioblastoma), which is partly justified by
the highly aggressive nature of these cancers (first year
prevalence of 1.6%), as well as of melanoma (an extremely
rare cancer). This misrepresentation is largely attributed
to AT-MSC (Additional file 4: Figure S4).
The shortage of naïve MSC-based research on targeting
highly frequent and lethal cancer types clearly necessitates
more focused work to be carried out. Moreover, there is
an excessive concentration of research efforts utilizing
MSC against tumors (e.g., breast), which have failed to
produce patient-beneficial results, as it is discussed below.
Differential effects of naïve BM-, AT-, and UC-MSC on tumor
targets
Following on from addressing the frequency, distribution
and clinical relevance of cancers targeted in naïve
MSC-based cancer cytotherapy, we set on to evaluate
the anti-cancer behavior and efficiencies of the three
MSC types relative to each other. Our meta-analysis
showed a differential pattern of anti-carcinogenic behav-
ior, with BM-MSC generally being pro-tumorigenic, and
UC-MSC having a more clear onco-suppressive charac-
ter (Fig. 3c). More specifically, overall, UC-MSC is the
MSC type most commonly associated (about 50% fre-
quency) with suspension of development of its tumor
Fig. 2 Representation of common cancer types in MSC-based cytotherapy studies compiled in this review in comparison to global cancer
incidences (clinical relevance). The most frequently targeted tumors in cancer cytotherapy studies have been ranked in descending order of
worldwide cancer incidence (2012 data) [122] from left to right on the x axis. Global cancer incidence rates are depicted as solid line symbols
(boxed values), while the frequencies of tumors targeted by unmodified/naïve MSC (n-MSC) or genetically modified MSC (GM-MSC; see also the
“Genetically modified MSC as delivery vehicles for antitumorigenic molecules—overview and meta-analysis results” section) in experimental
cancer cytotherapy (CT), as determined by our meta-analysis, are represented by black (n-MSC CT) or white (GM-MSC CT) columns, respectively.
Sample sizes: N = 79/N = 67 for n-MSC- and GM-MSC-based work, respectively. For each cancer type, the difference in height between the solid
line symbols and the column bars denotes the divergence in representation of global cancer incidence by CT work, with positive differences
(global % > MSC CT %) signifying under-representation, and negative ones (MSC CT % > global %) over-representation of cancer incidence. For
example, the two most under-represented tumors targeted by n-MSC CT are those of lung as well of liver/stomach/pancreas (HGP) (by 12.3% and
8.5%, respectively), while the most over-represented ones are those of breast and brain (difference of − 11.3 and − 8.3, respectively), see the main
text (the “Relevance of preclinical cancer cytotherapy targeting to global cancer incidence” section) for further discussion. Overall, the data
suggest that in order for experimental CT work to become more clinically relevant, more focus should be put on the following, under-
represented tumor targets: * Hepatic/gastric/pancreatic (HGP) tumors (using both n-MSC and GM-MSC). * n-MSC-based lung cancer cytotherapy. *
Colorectal cancer targeted by both n-MSC (especially UC-MSC) and GM-MSC. * Prostate cancer targeted by GM-MSC (especially UC-MSC), as well
as n-MSC. * GM-UC-MSC-based brain tumor cytotherapy
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targets (Fig. 3a), while concomitantly having the lowest
association (< 10%) with tumor promotion (Fig. 3b),
which notably is observed only in relation to in vitro ex-
perimental work (Additional file 5: Figure S5). On the
contrary, BM-MSC promote cancer progression in the
majority (~ 70%) of the experiments conducted both in
vitro and in vivo, at least twice as frequently as AT-/
UC-MSC (Fig. 3b). On the other hand, AT-MSC’s
anti-cancer behavior is the least prominent relative to
the other two MSC types (20.5% for AT-MSC, vs. 29.5%/
49.5% for BM-/UC-MSC frequency of onco-suppressive
action towards tumor targets in vitro and in vivo)
(Fig. 3a).
Switching the focus to the specific types of tumors
with markedly affected progression—either positively or
negatively—by MSC administration, our meta-analysis
revealed the following associations (Fig. 4). First, the
tumors most frequently suppressed by naïve MSC in the
available cytotherapy in vivo and in vitro studies are
those of the breast, lung, and brain, as well as the liver,
stomach, and pancreas (Fig. 4a). UC-MSC are mainly re-
sponsible for suppressing breast and lung cancers (73%
and 63% contribution, respectively), while AT-MSC are
associated with glioma/glioblastoma inhibition in the
majority of cases (57%), relative to the other MSCs. Sec-
ond, with respect to tumor promotion, there is a strong
association of BM-MSC with breast and colorectal can-
cer (79% and 88%, respectively) and of AT-MSC with
melanoma. UC-MSCs, on the other hand, have minimal
or no association with carcinogenesis induction for these
three tumors (Fig. 4b). A parallel analysis based on con-
solidated MSC groups confirmed the pro-tumorigenic
effect of BM-MSC on breast and colon, as well as the
antitumorigenic effect of UC-MSC on breast and lung
Fig. 3 Anti-cancer efficiencies of naïve MSC isolated from adult bone marrow (BM), adipose tissue (AT) or fetal umbilical cord (UC). a Radar graph
depicting differences in frequencies of UC- (red), BM- (black), or AT-derived (blue) MSC associated with tumor suppressive activity in vivo and/or
in vitro. The tumor suppression frequency for each MSC type relative to the other two is represented by vertical distances from graph center.
Each outer vertex represents the maximum frequency (100%), equal to the sum of the three relative frequencies of the respective MSC types.
Suppression rates are shown for four consolidated groups (presented in ascending order of size clockwise starting from “in vivo”). Values for the
highest suppression rate in each of the four groups are shown. b Radar graph depicting differences in frequencies of UC- (red), BM- (black), or
AT-derived (blue) MSC with respect to pro-tumorigenic behavior in vivo and/or in vitro. The tumor promotion frequency for each MSC type
relative to the other two is represented by vertical distances from graph center. Each outer vertex represents the maximum frequency (100%),
equal to the sum of the three relative frequencies of the respective MSC types. Promotion rates are shown for four consolidated groups
(presented in ascending order of size clockwise starting from “in vivo”). Highest observed values for each of the groups are shown. c Distribution
of pro- vs. antitumorigenic effects for each of the three naïve MSC types in vitro and in vivo (N = 26/46/25 for AT-/BM-/UC-MSC, respectively). In
the case of UC-MSC, all pro-tumorigenic effects were observed in vitro
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cancers, and of AT-MSC on neural tissue tumors
(Table 1). Unfortunately, due to sample size constrains,
the analysis could not resolve any possible differences
between in vivo and in vitro effects. Nevertheless, it vali-
dated breast cancer, as not only the most common
cytotherapy target but also the only one being both sup-
pressed and promoted by naïve MSC (UC-MSC and
BM-MSC, respectively).
Obviously, the origin of the MSC population used for
administration in animal tumor models plays an instru-
mental role in determining the fate of the treatment.
Our analysis has shown that, in terms of anti-cancer effi-
cacy, naïve BM-MSC despite the plethora of studies re-
ferring to their use in cytotherapy protocols, perform
rather inefficiently. This is supported by the fact that
they present the worst in vitro anti-cancer performance
as discussed further on, they are frequently associated
with tumor promotion both in vivo and in vitro (Fig. 3),
and they are the only MSC type with validated
tumor-promoting effects against at least three different
tissues, including breast and colon (Fig. 4, Table 1). Most
notable is the case of breast, in which tumor promotion
was verified in vitro using three different cancer cell
lines by five independent groups [33, 56, 58, 74, 76]. Fur-
thermore, also worth noting is that, in contrast to
BM-MSC, UC-derived stem cells show much greater po-
tential as candidates for cancer cytotherapy. This is sup-
ported by the following trends (Figs. 3, 4, and 5 and
Table 1); UC-MSC are (1) the only MSC type with no re-
ports of tumor promotion in vivo (regardless of the
xenograft model they are used in) and no confirmed re-
ports in vitro in over 30 studies so far). This attribute
alone makes the safest candidate for clinical trials for
MSC-based cancer therapy. (2) UC-MSC are the MSC
type with the most robust antitumorigenic activity
(against breast and lung). The association with breast
tumor suppression is particularly strong with many inde-
pendent studies confirming it [69–73]. In comparison,
the majority of studies targeting brain tumors using
AT-MSC attribute an antitumorigenic behavior to the
latter, while naïve BM-MSC, as stated before, have yet
no proven therapeutic value. Moreover, with breast and
lung accounting for 41% of tumors, the anti-cancer be-
havior of UC-MSC is clinically relevant too. With re-
spect to the last point made, one should take into
account the limited number of studies available on other
important tumors such as colorectal, prostate, and liver
(see also Fig. 2) that do not allow any sound conclusions
to be made regarding the effect of naïve UC-MSC on
them. (3) UC-MSC are the only MSC with essentially no
Fig. 4 Cancer types most frequently associated with naive AT-/BM-/UC-MSC according to the type of anti-cancer effect produced (suppression or
promotion) in vitro and in vivo. a The colored central pie chart depicts the distribution of the four most common tumors upon which naïve MSC
were found to have a detrimental (onco-suppressive) effect. The percentage of relative association of each MSC type with each of the tumors is
represented by the respective gray-scale peripheral pie chart. The type of MSC most frequently associated with its target tissue and the frequency
(%) value are highlighted with a white box within the peripheral pie chart. Total sample size = 54 experiments using solely naïve MSC or naïve
MSC as controls for GM-MSC-focused work. Only tumor targets with a minimum sample size of seven (N ≥ 7) are shown. b The colored central
pie chart depicts the distribution of the three most common tumors associated with a supportive function (tumor promotion) of MSC. The %
relative association of each MSC type with each of the tumors is represented by the respective gray-scale peripheral pie chart. The type of MSC
most frequently associated with its target tissue and the frequency (%) value are highlighted with a white box within the peripheral pie chart.
Total sample size = 50 experiments using solely naïve MSC in addition to naïve MSC used as controls for GM-MSC-focused work. Only tumor
targets with a minimum sample size of seven (N ≥ 7) are shown. In the case of colorectal cancer, the absence of UC from the MSC pie is due to
the lack of relevant studies, rather than the lack of tumor promotion on the specific target
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Table 1 Summary table of main experimental parameters and outcome as determined by the meta-analysis of cancer cytotherapy
studies using naïve (unmodified) MSC
Consolidated groups N MSC MSC N Tumors most frequently
targeted (%)
Tumor target
frequency (%)
Mean antitumor effect*
In vivo (naïve) 30 AT 5 Brain/neural 60 ND
BM 20 Breast 25 ND
Colorectal 25 ND
UC 5 Breast 40 ND
In vitro (naïve) 53 AT 10 Breast 30 ND
BM 22 Breast 32 ??
UC 21 Breast 33 ANTI-
In vitro + in vivo (naïve) 83 AT 15 Brain/Neural 40 ??
BM 42 Breast 29 PRO+
Colorectal 19 PRO+
UC 26 Breast 31 ANTI-
In vitro + in vivo x(naïve+naïve as
CTRL for GM)
126 AT 31 Brain/Neural 32 ANTI-/NEUTRAL
BM 59 Breast 24 PRO+
Colorectal 15 PRO+
Liver 12 ??
UC 36 Breast 33 ANTI-
Lung 17 ANTI-
Findings based both on studies focusing solely on naïve MSC, as well as on selected studies where these cells were used as controls for experiments focusing on
genetically modified MSC (GM-MSC) are shown. Results are listed in consolidated groups of increasing size (number of observations = N). MSC N column depicts
MSC sample size. Primary outcomes include percentage of the most frequently targeted tumor types by the respective MSC, as well the mean anti-cancer effect
for each MSC (effector): tumor combination. The minimum accepted number of MSC (cut-off) most commonly associated with respective tumors was set to six
*PRO+ denotes tumor-promoting effect exerted by >50% of the associated MSC
ANTI denotes inhibition of tumor by >50% of the associated MSC
?? denotes no clear effect
ND not determined due to insufficient data (N < cut-off)
Fig. 5 Relationship between adoption of experimental model in vivo (animal model) and in vitro (culture format) and outcome of naïve MSC-
based cancer cytotherapy experiments. a In vivo. Bar of pie chart categories denote relative contribution of MSCs to the most frequently
observed outcome for each animal model. Naïve MSC plus naïve MSC used as controls for GM-MSC-focused work were used to derive total
sample size. For experiments on athymic- nude mice, N = 30. For experiments on SCID mice, N = 17. b In vitro. Co-C = direct or indirect co-culture
of naïve MSC with cancer cells. C.Med = use of naïve MSC-conditioned media on cancer cells. Sample sizes: N = 23/29/29, for
AT-/BM-/UC-MSC, respectively
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contradictory outcome reported (e.g., both pro- and
antitumorigenic against the same tumor target). On the
contrary, the latter is true for both BM-MSC and
AT-MSC (BM-MSC vs. colon cancer in vitro [57, 60];
AT-MSC vs. brain tumors [62–64]). (4) UC-MSC are the
only MSC type (as witnessed by in vitro experimenta-
tion, discussed further on) that can efficiently act upon
its tumor target indirectly through its secretome, with-
out any physical contact or crosstalk with components
of the tumor microenvironment.
Exploring the role of experimental parameters on MSC-
based cancer cytotherapy outcome
As discussed earlier, one of our main hypotheses was
that the experimental conditions could be determining
factors for the pro- or antitumorigenic behavior of MSC.
Thus, technical variation can supplement biological het-
erogeneity as a co-founding factor for the discrepancies
observed in tumor modulation by naïve MSC in cancer
cytotherapy protocols. The propensity of MSC to either
support or suppress tumor growth is the outcome of the
combination of multiple parameters, such as donor-to-
donor (epi-) genetic variability, heterogeneity in the iso-
lation of the original MSC population, heterogeneity due
to in vitro cell propagation, differences in the character-
istics of the in vivo tumor model adopted, divergence in
the choice of cell dosing (MSC: cancer cell infusion ra-
tios), and timing of administration (co-infusion vs. MSC
administration at early or advanced stage pre-established
tumors).
Consequently, the classification of data extracted from
studies in the literature as experimental parameters in our
database was integral to our meta-analysis methodology
approach. The parameters examined included choice of
cell culture format/ animal model, cancer cell lines, in vivo
cell administration scheme (route and timing), and MSC
to cancer cell ratio. This was done in order to investigate
the influence of each parameter alone or in combination
in shaping cytotherapy outcomes and contributing to het-
erogeneity (Fig. 5, Tables 2 and 3).
Although we are anything but close to identifying the un-
equivocally ideal conditions under which MSC will be able
to diminish tumor growth, findings that stemmed from
analyses of core parameters in our study combined with the
state-of-the-art knowledge could help build some general-
izations regarding optimal conditions; these are discussed
in the following lines and summarized in Table 3.
With regard to the experimental model adopted, our ana-
lysis showed that the animal model employed in in vivo
cytotherapy protocols, and, in parallel, the cultivation con-
ditions (culture format) of effector and target cells in vitro,
could be decisive factors for the fate of MSC-based treat-
ments (Fig. 5). At this point, it is worth highlighting that
the in vivo work included in our analysis comprised
preclinical cancer cytotherapy models in which human
primary MSC were implanted in immune deficient/immu-
nocompromized rodent hosts (SCID or athymic nude mice
variants) bearing human tumor xenografts. Syngeneic
models or models bearing non-human MSC (which consti-
tuted 10–15% of the total) were not taken into consider-
ation. Although this exclusion limited the amount of
studies, hence, the number of data available for statistical
analysis, it on the other hand constrained heterogeneity at-
tributed to differences in native antitumor immune re-
sponses and, most importantly, in homology of expressed
molecules between therapeutic cells and target cells [123].
Although both xenograft models included in our analyses
provide excellent representation of human disease allowing
the engraftment, growth, and interaction of human MSC
and human cancer cells, the majority (two thirds) of the
studies were conducted on athymic mice. The latter bear
the advantage of being less immunodeficient than SCID
variants, therefore more convincingly recapitulate immune
system- affiliated antitumor therapeutic responses and dis-
ease progression [124]. As shown above, overall, the vast
majority of tumor promotion effects are exerted by
BM-MSC (Fig. 3b), while in the case of suppression there is
no such clear contribution by a specific MSC type (Fig. 3a).
With regard to the animal models used, one would expect
tumor promotion to be more frequently observed in SCID
mutants (severely deficient in functional B and T lympho-
cytes), rather than in athymic nude mice, which are less
immunocompromized, bearing more active B cells and in-
tact innate immunity through robust natural killer (NK-)
cell responses. Yet, it is the majority of experiments (53%)
in athymic mice in which tumorigenesis is promoted;
largely responsible for this outcome are BM-MSC (Fig. 5a).
This could be possibly explained by the immunomodula-
tory function of MSC which have proved to be able to in-
hibit T and B, as well as NK cells, suppressing thereby any
possible adaptive immune responses [97–99]. Moreover, it
has been proposed that active B cells, which in this case
may escape MSC targeting, promote acute innate inflam-
mation, which in turn impels malignant progression [125].
Furthermore, in the late 1990s, Barbera-Guillem and col-
leagues showed that immune complexes formed by anti-
bodies and tumor-associated antigens (TAA) can promote
tumor progression, through a mechanism that involves the
activation of a crosstalk between polymorphonuclear
(PMN) leukocytes and monocytes [126]. From this aspect,
the potential interactions between injected MSC and the
nude animal’s activated B lymphocytes could trigger tumor
progression through a mechanism that is T cell independ-
ent. In any case, all these mechanisms might be more
prominently activated in the case of BM-MSC, since im-
pressively, as aforementioned, UC-MSC do not promote
tumorigenesis in vivo, and this is regardless of the immuno-
logical background of the xenograft host. This is most likely
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attributed to the unique immunomodulatory properties of
these cells, with their antigenicity not necessarily triggering
tumorigenicity (further discussed in the following section).
In vitro cancer cytotherapy experimental models com-
prise two main types: (a) co-cultures of MSC and cancer
cells, where cells communicate (two-way interaction) ei-
ther directly through physical contact and the formation
of gap junctions, or indirectly via exchange of soluble
factors (crosstalk), and (b) monocultures of target
(tumor) cells, which are grown in and react to culture
media in which the effector cells (MSC) have been
grown for 24–48 h (conditioned media (CM)). This sec-
ond culture model basically allows only unilateral signal
communication (from the effector to the target/re-
sponder cell). In both experimental settings, BM-MSC
had mainly pro-tumorigenic effects on cancer cells, while
on the contrary, UC-MSC were mostly antitumorigenic
(Fig. 5b). In vitro, the frequency of association of UC-MSC
with tumor-promoting events is very low (2–12 times lower
than in case of adult MSC). More interestingly, the associ-
ation of UC-MSC with antitumorigenic activity is quite ro-
bust (> 70% frequency), irrespective of the culture model
adopted. A moderate or strong tumor suppressive effect of
UC-MSC-CM has been observed against a group of cancer
targets much more diverse than in the case of adult MSC;
these include the bladder [83], breast [68, 71], larynx [127],
lung [128], glioma [129], lymphoma [130], melanoma [131],
osteosarcoma, and ovarian adenocarcinoma [70]. Conse-
quently, UC-MSC bear quite robust anti-malignant behav-
iors in vitro, with their secretome alone being strongly
tumoricidal, suggesting that they possess superior inherent
anti-cancer properties, being effective solely in a paracrine
Table 2 Contribution of experimental parameters/variables on cytotherapy outcome. The following parameters were examined
A. Tumor suppression vs. cancer cell lines (in vivo/in vitro)
MSC Breast cancer cell line
MCF-7 MDA-MB-231 All cell lines
BM/AT/UC 17/ND/75 (75) 0/ND/60 (85.7) 36/20/56.3 (82)
All MSC 36 46 34.4
B. Tumor suppression vs. cell administration scheme (in vivo)
MSC In vivo cell administration scheme
Co-injection of MSC + cancer cells Administration of MSC in established tumors
BM/AT/UC 11.8 (50)/10 (0)/ND 64.7 (72.7)/50 (100)/64 (66.7)
All MSC 14.3 (25) 61.5 (75)
C. Tumor suppression vs. MSC: cancer cell ratio (in vivo)
MSC MSC: cancer cell ratio (in vivo)
MSC: cancer < 1 MSC: cancer ≥ 1
BM/AT/UC 36.4/33.3/71.2 25/12.5/66.7
All MSC 45.8 30
D.
Consensus of in vivo cytotherapy experiments
Effect on tumor MSC type Mouse model Admin. route MSC dosage
(millions)
Ratio (MSC to
cancer cells)
Repeated
dosing
Effector-target overlap
period (days)
Total experiment
duration (days)
ANTI- (N = 19) NA NA NA 1 1:2 NA 22 ± 19 30 ± 23
PRO- (N = 27) BM Athymic/nude s.c./s.c. 1 1:1.35 No repeat 39 ± 22 40 ± 24
A. Type of tumor-specific cell line targeted. Tabulated values denote breast tumor suppression rates (%) caused by MSC after interaction with various breast cancer
cell lines, including the two most common ones, MCF-7 and MDA-MB-231, in vitro and/or in vivo. Νumber of experiments N = 11 (MCF-7), 14 (MBA-MB-231), and
32 (all eight cell lines). ND not determined due to insufficient data (N < 5). Numbers in brackets (UC-MSC) correspond to percentage of suppression if neutral
effects are not taken into consideration. Data show a more robust tumor suppressive effect of UC-MSC (in italics) which seems be cancer cell line-independent. B.
Timing of in vivo cell administration. Tabulated values denote percentages (%) of inhibitory effects caused by MSC on tumors in in vivo experiments, in which MSC
were administered either simultaneously (co-infused) with cancer cells in animal models or sequentially in established tumors. The number of experiments
recorded for the two modes of administration were N = 27 and 39, respectively. ND not determined due to insufficient data (N < 5). Percentages in brackets: sub-
portion of samples in which a strong (over twofold) suppressive effect was observed. Data show that MSC have a more prominent suppressive effect when
delivered to pre-established tumors. C. Cell dosing ratio. Tabulated values denote percentages (%) of tumor suppressive effects of MSC in in vivo experiments,
depending on the relative number of administered MSC (effector cells) to cancer (target) cells (MSC to cancer ratio). The effects of two such ratios are compared:
MSC: cancer < 1 (cancer cells in excess) vs. MSC: cancer ≥ 1 (MSC in excess). Percentages refer to the proportion of experiments with antitumorigenic results out of
the total number of experiments in each ratio. The number of experiments recorded for the two ratios were N = 24 and 30, respectively. Data indicate a stronger,
by over twofold, tumor suppressive effect of AT-MSC when used at the lower MSC dosing ratio (values in italics). See also section 4.1.3 for further discussion. D.
Combination of the typical, most frequently observed (> 50% frequency) parameters of in vivo experiments using naïve MSC. Typical experimental parameters
related to anti- or pro-tumorigenic effect of MSC are shown. NA data associated with the respective parameter gave no clear consensus. Highest suppression rates
are highlighted in italics (where applicable)
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fashion with a non-essential need for physical cell contact.
Taken together with their performance in vivo, UC-MSC
exhibit very low probability of eliciting tumor initiation or
progression in experimental cancer cytotherapy, thus laying
the foundation for their safe inclusion in clinical trials.
With respect to the diversity of tumors targeted,
our analysis included over 15 tumor types represented
by more than 60 well-characterized human cancer cell
lines. The cancer types with the highest number of
available cell lines were the breast and brain (eight
and seven cell lines each, respectively). Nevertheless,
it is interesting that only 12% of the studies used two
or more representative cell lines to describe and con-
firm the observed effects on the tumor tested. In an
effort to test whether MSC exhibit distinct behavioral
imprints on different cell lines of the same cancer tis-
sue, we focused on breast cancers, since not only they
were the most popular tumor target, but also the one
represented by a large number of cell lines, as stated
above. We compared data from two of the most com-
monly used cell lines, MDA-MB-231 and MCF-7, vs.
all eight available breast cancer cell lines (Table 2A).
Interestingly, the tumor suppression rate overall did
no differ significantly with respect to the cell line but
as a function of the MSC used, with UC-MSC having
clearly a more profound effect than the other two
MSC types. This is despite the differences in the
characteristics of the cell lines examined, with
MDA-MB-231, a triple negative, aggressive breast
cancer cell line, being more prone to cytotoxicity, and
MCF-7 more robust and resistant, as evidenced by
chemotherapeutic treatments. Thus, although these
results are only indicative, it would be logical to as-
sume that for at least some cancers, the biological
differences between MSC are a greater source of het-
erogeneity than the genotypic and phenotypic diver-
sity of cancer cell lines. Nevertheless, it is proposed
that the effects of MSC against a given cancer should
be examined and verified by at least two cancer cell
lines, ideally with distinct characteristics.
Our analysis has also highlighted the cell administra-
tion scheme adopted (i.e., the route and timing of MSC
and tumor cell infusions) as one of the key factors influ-
encing cancer cytotherapy outcome. Cross-examination
of the data in Tables 2B and 2D reveals that simultan-
eous administration (co-infusion) of MSC and cancer
cells in studies in rodents results in poor anti-cancer ef-
ficacy (14.3% suppression). In sharp contrast, delayed ad-
ministration of MSC (usually infused orthotopically or
intravenously, 7–10 days after initial tumor cell delivery)
dramatically ameliorates both the occurrence and sever-
ity of tumor suppression (by over fourfold and threefold,
respectively). This observation is consistent with the hy-
pothesis that the presence of MSC during early tumor
establishment events may actually facilitate processes,
such as angiogenesis, which are required for tumor initi-
ation [93].
In terms of cell dosing, MSC-to-cancer cells ratios
lower than one (< 1) (i.e., cancer cells in excess) seem
overall to be better associated with tumor inhibition in
vivo (45.8% vs. 30% for ratios > = 1) (Table 2C). Interest-
ingly, the effect is more prominent for adult MSC, espe-
cially. AT-MSC, while UC-MSC seem to retain their
high effectiveness towards cancer growth irrespective of
the cell dosing ranges applied (Tables 2C and 3). In the
case of BM-MSC, tumor promotion occurring when
relatively high numbers of MSC are used has been found
to correspond to the immunosuppressive functions of
these cells that are known to be more active at higher
MSC numbers but lost at low doses [132, 133] (see also
the “Linking MSC phenotypic differences to variation in
anti-cancer efficacy” section).
As a final step in our analysis, we attempted to derive
a consensus of experimental parameters affiliated to ei-
ther tumor suppression or promotion by recording the
frequently observed (> 50% frequency) value in each
case. Although the data did not allow a consensus to be
built in the first case, a set of parameters were identified
that could be regarded, either alone or in combination,
as “tumor promotion-statistically associated experimen-
tal parameters” in preclinical cytotherapy studies. Such
factors are listed in Table 2D. Thus, according to our
findings a single co-injection of tumor cells and human
naïve BM-MSC at a ratio of 1.5:1 to 1:1, subcutaneously
(unnatural tumor growth site) in athymic mice would
most likely maximize tumor initiation and growth.
MSC isolation and expansion in experimental
cytotherapy—sources of variation and implications for
clinical trials
The process of in vitro/ex vivo MSC expansion is neces-
sary in order to obtain clinically significant cell numbers.
This procedure is nevertheless time-consuming, costly,
and poses cell contamination and loss risks, thus ideally
the MSC source should allow the relatively easy,
high-yield isolation of populations with propagation
characteristics that minimize sub-cultivation time.
A large number of studies have unequivocally demon-
strated that variations in ex vivo manipulation condi-
tions, such as age and anatomical origin of donor tissue
[134, 135] harvesting procedures [136], type of culture
medium, including type of constituent growth serum-
[137, 138], initial plating and sub-culture seeding dens-
ities, and culture period/number of serial passages [139,
140], either separately or in combination [141], can have
a major impact on proliferation and other vital processes
(stemness/ differentiation, secretion) of all stem cell
types, albeit to different extents.
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The contribution of MSC expansion on the discrepan-
cies observed regarding their antitumor behavior can
only be speculated, since astonishingly, no preclinical
cancer cytotherapy study so far has focused on evaluat-
ing the effect of variations in sub-cultivation characteris-
tics of a given MSC type on specific cancer types. This
would be particularly interesting as it would not only
pinpoint the impact of this source of variation on
cytotherapy efficacy but also on adequacy and would aid
towards the establishment of some rudimentary good
manufacturing practice (GMP) standards in light of the
clinical trials [142].
With regard to the differences in ex vivo expansion be-
tween various MSC types, a significant amount of studies
show that they are ontogeny-related, with many underlin-
ing the superiority of MSC isolated from fetal umbilical
cord tissue, over those derived from adult tissues (bone
marrow and adipose tissue) [143–145]. More specifically,
the intervascular matrix of the umbilical cord (Wharton’s
jelly) contains the MSC population with arguably the best
isolation and expansion characteristics among its other
substructures (e.g., perivascular and subendothelial tis-
sues) [146–149]. On the other hand, AT-MSC are
regarded superior to BM-MSC, primarily due to the rela-
tively easier, higher-yield harvest method, and secondarily
due to their enhanced stability over prolonged sub-culture
[150–153]. Ιndeed, BM-MSC have the least favorable
characteristics in terms of tissue accessibility/abundance
for harvesting purposes since their isolation relies on inva-
sive, painful techniques that use aspiration needles to
reach their anatomical source (usually the marrow cavity
of the pelvic bones) and which are often associated with
patient-to-patient variability and donor site morbidity
[150, 152]. In sharp contrast, UC tissue is naturally col-
lected during normal parturition, and unless it is stored
for banking or research purposes, it is normally regarded
as medical waste and discarded [149].
With respect to ex vivo growth kinetics, UC-MSC bear
three distinct advantages over adult MSC. First, the isola-
tion procedure results in larger pool of adherent, clono-
genic cells (MSC), especially compared to BM-derived
MSC. There are various studies reporting a yield of
10,000–15,000 MSC per cm of umbilical cord tissue in the
starting culture [137, 146, 149, 154], while this can be fur-
ther increased by protocol modification [155, 156]. With
lengths of cord harvested ranging between 15 and 48 cm,
a typical isolation yield would be about 400,000 highly
proliferative UC-MSC [157–159]. On the contrary, adher-
ent BM-MSC represent a quite rare population in the
bone marrow, estimated at 0.0001–0.001% of total nucle-
ated cells (1–10 colony-forming unit–fibroblast (CFU-F)
per million of peripheral blood mononuclear cells) [160].
This actually equates to no more than a few hundred cells
per ml of marrow aspirate, with a typical yield not
exceeding 5,000 cells per 5 ml of aspirate [139, 161]. Re-
garding adipose depots, the reported frequency of nucle-
ated cells isolated is at least 0.4 million per milliliter of
processed lipoaspirate. However, plating efficiency of these
cells varies considerably (0.2–4 %) [161], so actual
AT-MSC turnover can range from 0.24–10 million cells
for liposuction volumes between 100–3000 mL (or a mean
yield of 0.9–1.3 million stem cells from an average 300 ml
(= 270 g) lipoarspirate) [152, 162]; this yield can be 500–
2500-fold greater than that of BM-MSC [136, 163, 164].
Second, UC-MSC proliferate at a much faster rate, various
studies report population doubling times (PDT) in the
range of 26–42 h until the fifth passage (which inciden-
tally is the most common sub-culture threshold used)
while for adult MSC it is 50–65 h [136, 137, 139, 149, 165,
166], although there are studies reporting PDT exceeding
96 h especially in the case of AT-MSC [143, 167]. This
equates to shorter culture periods required to obtain the
desired cell yield and thus makes UC-MSC more suitable
for clinical scale expansion (e.g., 30–40 days are required
to complete five rounds of expansion, as opposed to
2 months in the case of adult MSC) [168]. A yield of about
five billion UC-MSC from a single cord can be obtained
within 5–6 passages when large five-cell stacks are used
for propagation [138]. Third, UC-MSC can sustain their
higher proliferation rates for extended time periods. They
not only can be serially propagated up to eight or nine
times while maintaining a short PDT (< 30 h), but can be
additionally expanded up to 25–50 population doubling
(PD) (over 20 passages) while maintaining a normal karyo-
type as well as their immunophenotypical and stemness
characteristics [137, 158, 169, 170]. Differences of up to 22
PD have been observed between the proliferative lifespans
of BM-MSC and UC-MSC [168]. Impressively, yields up
to 1017 UC-MSC (40 PD) over a 2-month culture period
have been reported (in sharp contrast to only 5 × 107
(8PD) for BM-MSC) [171]. Interestingly, growth in low
O2 environment (5%) [138, 172] or in xeno-free culture
medium [173, 174] further enhances their proliferative
lifespan, while extracts of these cells when coated onto
cultures plates ameliorate late-passage proliferation of
both UC-MSC and BM-MSC [168]. On the contrary, adult
MSC show a limited potential for prolonged propagation,
being able to maintain only up to 15–25 PD (9–12 pas-
sages) in culture [153, 165, 168]. A senescent phenotype,
characterized by a plateau in the rate of PD accumulation,
a sharp reduction in cloning efficiency, and an increase in
positive β-galactosidase staining, has been observed in
some cases as early as only six PD/passages [166, 175,
176]. In fact a cumulative number of 20 or more PD and a
PDT > 60 h have been highlighted as thresholds for repli-
cative senescence in BM-MSC, with recommendations to
use cells at the lowest passage possible, preferably up to
fifth to sixth [142, 177, 178].
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With regard to the role of MSC expansion in cancer
cytotherapy in specific, we could not draw any conclu-
sions, since no detailed information/experimental data
were available (besides number of passages, in some
cases) regarding status of cells utilized (such as number
of cumulative cell PD, PDT, CFU-F scores, senescence
status). However, taking into consideration the growth
kinetics and bearing in mind that the optimal MSC: can-
cer cell ratio should be 1:1 to 1:2 (Table 3), one could at-
tempt to estimate the feasibility of scale up for clinical
use for each type of MSC. Assuming that both a tumor
(e.g., T1 palpable breast cancer) and a cancer cell (breast
cancer cell lines) are spheroids with diameters of 2 cm
[179] and 15 μm [180], respectively, one would need
12–24 billion MSC to treat a single tumor. According to
our estimations, starting from isolation, AT-MSC would
require seven serial passages over a month’s period in
order to generate this amount of cells. On the other
hand, UC-MSC after 3.5 weeks and the same number of
passages would accumulate 19 PD which would be suffi-
cient for treating 8–16 tumors. Last, the ex vivo expan-
sion characteristics of BM-MSC make these cells the
least favorable for clinical use. The eight rounds of
sub-culture required (equal to 22 PD) are not only the
longest (at 56 days, essentially making very difficult to
match any need for frequent, repeated dosing) but would
also bring the cells close, if not beyond, their senescence
threshold. Actually, presuming that this threshold is five
to six passages (15–16 PD), then the maximum yield
that BM-MSC could give is 100 times less than that re-
quired in our example, i.e., these cells can support pro-
tocols which require up to approximately 120 million
cells.
Linking MSC phenotypic differences to variation in anti-
cancer efficacy
In the introductory section, we gave a brief account of the
characteristics that MSC share and form the basis of their
adoption as valuable cytotherapy tools. Nevertheless, our
literature meta-analysis has revealed that with respect to
anti-cancer efficacy it is their differences in genotypic and
phenotypic attributes that are more important. This no-
tion is based on the observation that the most prominent
disparity in the outcome of cancer cytotherapy is MSC
(effector)-related. Some naïve MSC populations are more
effective against specific tumor targets, where others
underperform and may even prove deleterious for cancer
treatment. A prime example of the latter case is the
pro-tumorigenic effect of BM-MSC and AT-MSC on
metastatic breast cancer. On the contrary, UC-MSC show
an anti-carcinogenic response that is both strong and ro-
bust, i.e., less sensitive to experimental conditions such as
choice of ex vivo model and cell dosing. According to our
findings, based on the data available so far, fetal-derived
UC-MSC are safer to use and more frequently associated
with suppression of tumor growth than MSC derived from
human adult tissues. This is backed up by comparative
studies evaluating the anti-cancer effects of MSC of differ-
ent developmental origin [64, 129], although clearly more
such studies should be carefully designed and carried out,
in order to validate the notion that outcome of cancer
cytotherapy is primarily MSC ontogeny-related.
There is sufficient evidence in the literature suggesting that
the unique combination of the biological traits suited for giv-
ing UC-MSC their special role in human development actu-
ally allows them to serve a second purpose as naturally
anti-cancer capable cytotherapy agents. UC-MSC are primi-
tive cells falling in the developmental map between hESC
and adult stem cells [181]. They share biologic characteristics
with both stem cell types; however, they do not combine
them with attributes that pose as safety risks for cytotherapy.
Thus, similar to hESC and unlike adult MSC, they are con-
sistently positive for pluripotency and self-renewal markers
such as Oct-4, NANOG, LIF, SSEA-1, SSEA-4, Tra-1–60,
and Tra-1–81 [116, 117, 182, 183]. In opposition to hESC,
they do not form teratomas when injected in SCID mice [72,
154]. Moreover, as discussed earlier, they are capable of sus-
taining high proliferation rates for extended periods in cul-
ture (due to their longer telomeres and expression of
telomerase), while simultaneously maintaining anchorage de-
pendence, contact inhibition and serum dependence as
growth requirements, i.e., showing no signs of spontaneous
transformation [149, 154, 184, 185]. In contrast, human adult
MSC have been linked to malignant transformation as well
as karyotypic instabilities and epigenetic damage, raising
safety concerns [176, 186, 187]. These can arise as a result of
extensive ex vivo cultivation or prolonged exposure to tumor
cell-generated stimuli. For example, spontaneous malignant
transformation occurred in 45.8% of long-term (5–
106 weeks) cultures of human BM-MSC, resulting in mul-
tiple fast-growing lung deposits when injected into immuno-
deficient mice [188]. Furthermore, in contrast to UC-MSC, a
series of studies have provided evidence for transition of
BM-MSC to a TAF-like myofibroblastic phenotype and
hence contribution to tumor growth after long-term expos-
ure to conditioned medium of breast and ovarian carcinoma
cells [35, 89, 189]. Last, noteworthy is the implication of
BM-MSC as originating cells for sarcomas, most notably the
highly metastatic osteosarcoma [190, 191]. Nevertheless,
there is also evidence in support of the view that adult MSC
are safe for cytotherapy applications. With respect to
BM-MSC, Bernardo and colleagues did not observe any sign
of transformation or genomic instability after 25 passages/
44 weeks in culture, respectively [192]. Apparently, this is at-
tributed to their inability to escape replicative senescence
due to their short telomeres [193]. Similarly, spontaneous
transformation that was initially reported in human primary
AT-MSC, following long-term (4–5 months) in vitro culture,
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was later recognized as an artifact attributed to unnoticed
minimal cross-contamination with a fibrosarcoma cell line
cultured simultaneously in the same laboratory [194]. Last, a
meta-analysis comprehensively summarizing the safety of 36
clinical trials using intravascular delivery of adult MSC for
the treatment of non-neoplastic diseases did not find a sig-
nificant association between MSC use and the appearance of
malignancy [195]. Although the occurrence of malignancy as
a long-term adverse event in response to systemic MSC infu-
sion was as high as 24% (in non-randomized control studies),
the difference compared to control patients was not signifi-
cant, while none of the malignancies observed were formed
de novo.
Our analysis has provided quantitative evidence for
the poor anti-cancer performance of BM-MSC which
are the MSC type most frequently (74%, Fig. 3c) associ-
ated with tumor promotion overall; moreover, their
secretome scores very low in terms of tumor suppression
(20%, Fig. 5b) which means that these cells lack intrinsic
tumoricidal properties. On the contrary, UC-MSC bear
strong tumoricidal abilities that are both intrinsic, i.e.,
naturally occurring without the need for cellular cross-
talk, and extrinsic, i.e., arise after interaction with malig-
nant tumor cells, dead tumor cells, or other benign
cellular components of the tumor supportive stroma
[196]. In both cases, the effects can solely occur in a
paracrine manner, which nevertheless does not preclude
direct physical cell contact, whilst they involve the secre-
tion of multiple proteins (secretome). These include
molecules that induce cell cycle arrest and cell death
(e.g., tumor suppressors, caspases) on cancer cells [117],
as well as variety of immunomodulatory effectors (e.g.,
pleiotropic cytokines and growth factors) [197–199] with
mainly anti-inflammatory action. The antitumorigenic
effect of UC-MSC secretome preparations (in the form
of cell lysates or conditioned media) has been assessed
on a variety of cancer cells in vitro (discussed in the pre-
vious section), most often through evaluation of their
contribution to cell cycle arrest and apoptosis induction,
e.g., by determining changes in expression/activation sta-
tus of tumor suppressors (e.g., p53) [127, 130], initiator
and executor caspases (caspase-9 and caspase-3) [8, 129,
130, 200], and negative/positive apoptosis regulators
(Bcl-2, Survivin/Bax) [70, 127, 129, 130]. Upstream
apoptosis-mediating mechanisms shown to be involved
include JAK/STAT signaling [200] as well as regulation
of Akt phosphorylation [83] and intracellular H2O2 pro-
duction [130]. In fact it is possible that UC-MSC secre-
tome affects the regulation of key antioxidant enzymes
resulting in high levels of intracellular H2O2 in cancer
cells, production of reactive oxygen species, and in-
creased oxidative stress triggering apoptotic cell death,
an anti-cancer mechanism similar to that used by many
current chemotherapy drugs. Indeed, when UC-MSC
extracts are used in combination with doxorubicin, not
only they do not increase resistance to the drug, but they
also display an additive cytotoxic effect on target cancer
cells [201, 202].
Lately, it has become evident that MSC secretome-medi-
ated effects on cancer cells implicate the delivery of
bio-molecular cargo (such as mRNA, miRNA, and secreted
proteins) packaged into membrane structures called extracel-
lular vesicles (EV). MSC-derived EV (MSC-EV), which
mainly comprise the nano-scale, endosome-derived exo-
somes, and the larger microvesicles, are considered as potent
regulators of intercellular communication. The main
biological potency of MSC-EV is maintenance of tissue
homeostasis and mainly involves targeting housekeeping bio-
chemical activities; however, they are also believed to play an
important role in the dissemination of cancer phenotype.
Data so far suggest that MSC-EV are an integral part of auto-
crine and paracrine signaling events modulating expansion
of the tumor microenvironment, angiogenesis, and metasta-
sis. Little is known about the exact mechanisms but data so
far are indicative of complex regulation involving antagonis-
tic effects [203, 204]. Thus, not only MSC-EV cargo compos-
ition seems to vary depending on the MSC source ultimately
having a differential impact on tumor fate [205], but even
more interestingly EV isolated from the same MSC source
can have opposing effect depending on the type of tumor
target [83, 206].
With respect to the immune system-affiliated antitumor
effect of MSC, our meta-analysis did not allow us to make
any clear deductions regarding the differences between
fetal and adult MSC, since for the reasons explained earl-
ier we chose to exclude data derived from syngeneic
models which have proper antitumor responses (tumor in-
filtrating lymphocytes, macrophages, and myeloid-derived
immuno-suppressor cells (MDSCs)) and better represent
the contribution of the host microenvironment to the tri-
adic interaction of MSC: cancer cells: stromal supportive
cells. Nevertheless, the immunomodulatory properties of
fetal and adult MSC have been quite well documented in
comparison [105, 207, 208]; moreover, some excellent
studies employing syngeneic models provide an insight
into the immunomodulation-mediated tumor suppressive
effect of UC-MSC [209–211].
Differences in immunomodulation are believed to be dir-
ectly linked to the duality of results in experimental cytother-
apy of cancer. For example, polarization of BM-MSC
(through specific priming of Toll-like receptors (TLR)) into
proinflammatory or immunosuppressive phenotype directly
correlates to tumor suppressive or tumor-promoting effects,
respectively [104, 212]. The immunomodulatory effect can
be so powerful that can actually drive two opposing re-
sponses within the same MSC tumor model [213]. With re-
spect to differences in immunomodulation properties of
adult and perinatal MSC, three main assumptions can be
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made by examining the available literature; (1) the immuno-
suppressive properties of human UC-MSC are significantly
stronger than those of BM-MSC. (2) MSC respond to differ-
ent thresholds of inflammation depending on the type and
concentration of proinflammatory cytokines they are ex-
posed to by regulating, in turn, the cytokine secretion and
activation marker profiles on immune cells. (3) With respect
to activation of immune cells, mitogen-induced and
alloantigen-driven lympho-proliferation are modulated prob-
ably by different mechanisms, which are unique for
BM-MSC and WJ-MSC. The evidence that points towards
these conclusions originates mainly from in vitro work. Un-
stimulated UC-MSC exhibit a strong suppression of
lympho-proliferation, even at a very low dose (1% UC-MSC,
mononuclear cells (MNC)) compared to BM-MSC, inde-
pendent of the inductive stimuli (presence of mitogen or al-
loantigen) [214]. Priming of UC-MSC (but not BM-MSC)
with inflammatory stimuli (e.g., IFN-γ) further attenuates
lympho-proliferation in a mixed lymphocyte reaction (MLR)
containing allogeneic peripheral blood MNC. Nevertheless,
mitogen-induced suppression of lympho-proliferative re-
sponses is further enhanced upon exposure of BM-MSC
(and not UC-MSC) to inflammatory stimuli. UC-MSC
(along with AT-MSC) suppress both mitogenically and allo-
geneically activated proliferation of purified T cells better
than BM-MSC in a dose-dependent manner by secreting
high levels of LIF; furthermore, they maintain and promote
the expansion of T regulatory cells (T-regs) independently of
the MSC/Tcell ratio [183]. Last, with respect to B cell activa-
tion, UC-MSC when co-cultured with PHA-stimulated
MNC do not influence acquisition of lymphoblast character-
istics by B cells or their progression from non-activated to
early activated stage, in contrast to BM-MSC and AT-MSC
that exert an inhibitory effect [215].
The differences in immunomodulatory function be-
tween adult MSC and UC-MSC are not restricted to adap-
tive immune responses. Raicevic and colleagues have
demonstrated a lower reactivity to bacterial or viral infec-
tions involving innate immunity mechanisms. In MLR
containing CD3+ T cells, UC-MSC resist the neutralizing
effect of inflammation or TLR ligation on their immuno-
suppressive properties by lacking TLR4 expression and by
overproduction of HGF (almost 10-fold higher expression
compared to BM-MSC and AT-MSC) [216].
Recently, the unique immunomodulatory properties of
UC-MSC have been linked to secreted components of
their ECM. In a study involving a mouse corneal trans-
plantation model, Coulson-Thomas and colleagues
showed that UC-MSC actively suppress inflammatory
immune response of the host microenvironment by fa-
voring M2 macrophage phenotype (anti-inflammatory)
over M1 (proinflammatory) and by inducing maturation
of T-regs and inflammatory cell death. They do this by
secreting components of their unique glycocalyx which
constitutes the characteristic matrix in which the cells
naturally reside and function [217]. One of the proper-
ties with high practical utility in terms of cytotherapy is
their low immunogenicity, which is a key requirement
for allogeneic transplantation. UC-MSC/WJ-MSC, like
their adult counterparts, evade immune recognition by
lacking co-stimulatory molecule expression (CD40L,
CD80/CD86) which are normally implicated in activa-
tion of both T and B cell responses. However, crucially,
UC-MSC distinguish themselves from adult MSC with
respect to expression of major histocompatibility complex
(MHC) molecules. UC-MSC express significantly lower
levels of MHC class I (HLA-ABC) both at rest and follow-
ing stimulation with IFN-γ, while MHC class II (HLA-DR)
induction with IFN-γ treatment is substantially aug-
mented in BM-MSC but is very negligible in WJ-MSC
[169, 218]. The lower HLA class I and II expression profile
of UC-MSC leads to dampened immune recognition and
promotion of immune ignorance in vivo. It may also par-
tially explain the lack of sensitivity of responder cell prolif-
eration to UC-MSC doses, unlike BM-MSC where the
balance between their immunosuppressive/-supportive
properties is more emphatically determined by their direct
environment (relative cell ratios and physical contact). In-
deed, the fact that low MSC numbers may display a stimu-
latory instead of inhibitory activity on T cell proliferation
has been shown using mixed lymphocyte cultures [207].
BM-MSC may express MHC class II antigens and act as
antigen-presenting cells eliciting a strong T cell response
in the presence of low levels of IFN-γ, i.e., in an inflamma-
tory setting [219]. The expression of MHC class II mole-
cules on the surface of MSC requires autocrine
stimulation by endogenous, low levels of IFN-γ, but is de-
creased at high IFN-γ levels causing the loss of the
antigen-presenting cell function of the MSC HLA-DR
[220]. Interestingly, in a more recent study, it was shown
that HLA-DR-negative BM-MSC can augment or hinder
the proliferation of T lymphocytes depending on the cell
ratio used. Optimal MSC-mediated inhibition required a
high MSC: CD3+ ratio (1:4) and direct physical contact
between the cells [183].
Human UC-MSC have been also found to differ from
adult MSC with respect to the expression of HLA-G, a
non-classical HLA class I molecule which plays a key role
in maternal tolerance for the developing fetus [170].
UC-MSC, in contrast to BM-MSC, express high levels of
HLA-G which upon IFN-γ stimulation increase even fur-
ther. This high expression of soluble as well as
membrane-bound HLA-G isoforms allow UC-MSC to
suppress immune reactions by reducing allo-proliferation
of T cells, by disturbing the cytolytic function of NK cells,
and by preventing maturation of dendritic cells [221, 222].
HLA-G has been shown to mediate the suppressive func-
tion of UC-MSC on lympho-proliferation in MLR and
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thus their escape from immune recognition by allogeneic
peripheral blood lymphocytes [169]. The immunomodula-
tory activity of UC-MSC has been further demonstrated
by their ability to suppress the expression of proinflamma-
tory cytokines in vitro (such as TNF-α and IL-6) after
co-culture with peripheral blood MNC, and in vivo by
their survival as xenotransplants in immunocompetent
mice not receiving any immunosuppression.
Despite their immunosuppressive properties and low im-
munogenicity, under certain circumstances, UC-MSC can
elicit an immune response which should be taken into con-
sideration when establishing a cytotherapy protocol (e.g.,
timing of MSC administration). In a clinically relevant
miniature swine model, while a single injection of
MHC-mismatched inactivated UC-MSC did not elicit a de-
tectable immune response, repeated injections in the same
region caused the opposite effect, as evidenced by the pro-
duction of alloantibodies within 1 week [223]. Therefore,
care must be taken in order to avoid sensitization, especially
against orthotopic cancer cytotherapy.
Overall, ontogeny-related differences in the pattern of
expression of HLA molecules (e.g., HLA-DR, HLA-G),
as well as in the cytokine secretion profile (e.g., HGF,
LIF, IL-6) between adult MSC and UC-MSC are largely
responsible for the course of direct or indirect inter-
action with cellular components and bioactive factors of
the tumor microenvironment driving the adoption of a
tolerogenic/immunosuppressive or a more immunoreac-
tive/proinflammatory phenotype, which ultimately deter-
mines the impact on tumor progression. With this in
mind, the optimal dose, frequency, and timing of MSC
administration need to be carefully considered for each
cancer target.
Genetically modified MSC as delivery vehicles for
antitumorigenic molecules—overview and meta-analysis
results
Tumor specificity is the major obstacle hampering the
effectiveness of current cancer treatment therapies,
such as combination chemotherapy. Advanced drug
targeting of tumor cells is particularly hard when
treating highly invasive and/or metastatic tumors such
as glioblastoma or pulmonary cancer. Uncontrolled
drug distribution in the patient’s body, i.e., insufficient
concentration at the tumor site and toxic concentra-
tion in normal cells, which is attributed to inefficacy
of anti-cancer therapy, is often the direct cause not
only of severe side effects but also, ironically, of
life-threatening complications. MSC tropism towards
primary and metastatic tumor locations, which occurs
independent of tumor type, MSC immunocompetence
and route of delivery, combined with their relatively
ease of in vitro manipulation to express molecules
with anti-cancer action, naturally provides a solution
to drug specificity, bypassing the main issues of
stability (short half-life), dosing (effective dose vs.
maximally tolerated dose), and off-target toxicity (side
effects) associated with their systemic administration.
Historically, the therapeutic value of this unique
“Trojan horse/smart bomb” approach for the con-
trolled release of potent antitumorigenic agents in situ
has been rather convincingly demonstrated in a large
number of studies with genetically modified MSC
(GM-MSC) targeting an extensive range of cancers in
various experimental animal models [reviewed re-
cently by [224, 225].
In this review, we have concentrated on studies referring
to human tumor cells specifically targeted by human
GM-MSC of adult bone marrow, adipose tissue, and fetal
umbilical cord matrix tissue origin, herein termed
GM-BM-MSC, GM-AT-MSC, and GM-UC-MSC, re-
spectively (Additional file 6: Figure S6).
Our meta-analysis has revealed that the focus of
GM-MSC-based cancer gene therapy experiments is on tu-
mors difficult to treat, i.e., highly invasive and metastatic
cancers (Fig. 2 and Additional file 6: Figure S6). Indeed, one
of the most frequently used models is that of metastatic
lung cancer (19.7%) which is in alignment with highest inci-
dence and mortality of this type of cancer worldwide. Brain
tumors, which are practically incurable, feature also quite
often as targets in GM-MSC-based work (21.2% frequency)
essentially serving as excellent proof-of-principle studies.
Nevertheless, GM-UC-MSC are clearly under-represented
in relation to brain cancer cell-mediated gene therapy. In-
deed, according to our analysis there is a bias (also observed
in the case of naïve MSC-based cytotherapy) in favor of
BM-MSC (48% frequency of use) with only one in five
(21%) of GM-MSC-based studies actually employing the
use of UC-MSC over adult MSC. Interestingly, breast can-
cer’s overall popularity as a target in in vivo anti-cancer
work employing GM-MSC is more than threefold reduced
(to 11%) relative to naive-MSC-based experiments, prob-
ably justified by the strong performance of naïve UC-MSC
against this type of tumor. Also in contrast to naïve MSC,
the range of tumors targeted in GM-MSC-based cytother-
apy is somewhat more limited. Sarcomas (Kaposi’s, osteor-
sarcoma), lymphomas (Burkit’s, non-Hodgkin’s), and
bladder and larynx tumors are notable omissions in GM-fo-
cused work.
In terms of anti-cancer efficacy, a number of studies
have convincingly demonstrated the therapeutic potential
of GM-BM-MSC against lung [33, 226–230] and brain
[231–237] cancers and of AT-MSC and UC-MSC on brain
[238–241] and breast [72, 73, 200, 242] tumors, respect-
ively (Additional file 6: Figure S6). With regard to
GM-AT-MSC and neural tissue tumors, the robust
anti-cancer performance of the former counterbalances
the erratic behavior of their unmodified precursors, while
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in the case of breast cancer and UC-MSC the results ob-
tained using GM protocols solidify the already encour-
aging results obtained using naïve UC-MSC.
Overview of GM strategies applied
High clinical relevance of tumor targeting in
GM-MSC-based cancer gene therapy is especially im-
portant since the latter has showed consistently high
anti-cancer efficacy in terms of inhibition of local tumor
growth, suppression of metastasis, or prolongation of
animal survival, irrespective of the experimental meth-
odology. With regard to the latter, apart from the ef-
fector (MSC)-target (tumor) components, the choice of
transgene (anti-cancer agent) that is incorporated into
the MSC carrier, as well as the enabling genetic modifi-
cation technology, complete the list of methodological
components. The two main strategies adopted are (a)
the rather straightforward overexpression of molecules
with known antitumorigenic action or (b) gene-directed
enzyme/prodrug treatment (GDEPT) (Table 4). In the
first case, MSC are transduced with molecules which
upon expression are usually secreted acting via different
mechanisms on tumors and range from immune regula-
tors such as interferons (e.g., IFN-alpha, IFN-beta,
IFN-gamma) [33, 128, 200, 227, 229, 243–245] interleu-
kins (e.g., IL-12, IL-21) [246–248] and chemokines (e.g.,
CXC3L1) [228], to molecules with pro-apoptotic (e.g.,
sTRAIL) [226, 232, 234, 235, 249–253], anti-angiogenic
(e.g., Alpha1-anitrypsin, NK4) [254, 255], or other prop-
erties (e.g., PEDF, TNF-a, HNF4-a) [54, 237, 256–258].
Among these, immune response modulators and
pro-apoptotic agents are the most popular transgene
classes used, with an adoption rate exceeding 60%
(Table 4). The most frequently adopted representatives,
IFN-β and TRAIL, which together account for more
than 40% of all human transgenes used in GM-MSC-
based experimental cancer cytotherapy, are incorporated
with the aid of viral vectors (usually adenovirus and
lentivirus, respectively) into BM-MSC and UC-MSC
markedly enhancing their anti-cancer efficacy.
Tumor necrosis factor-related apoptosis-inducing lig-
and (TRAIL) is a type II transmembrane protein of the
tumor necrosis factor (TNF) family of ligands that is
expressed by a variety of immune cells and is capable of
initiating apoptosis through engagement of its receptors
which are differentially expressed in normal and cancer
cells [259]. The attractiveness of TRAIL as a therapeutic
agent for the treatment of experimental cancer lies in its
ability to selectively induce apoptosis in a broad
spectrum of tumor and transformed cells, but not most
normal cells. TRAIL initiates a caspase 8-dependent
apoptosis signaling cascade by forming homotrimers that
bind cognate agonistic receptors DR4 (TRAIL-RI) and
DR5 (TRAIL-RII) bearing a conserved death motif on
target neoplastic cells. Apart from the membrane-bound
form, TRAIL can also exist and function as a soluble lig-
and. Its extracellular C-terminal domain can be proteo-
lytically cleaved from the cell surface in a
vesicle-associated or in a soluble form (sTRAIL) that is
also able to oligomerise and trigger p53-independent
apoptosis via binding to the cytoplasmic part of DR4
and DR5 on target cells [260]. And since most chemo-
therapeutic drugs and radiation act by inducing tumor
cell apoptosis in a p53-mediated manner via activation
of the intrinsic mitochondrial pathway, sTRAIL can be
used complementarily to overcome resistance to conven-
tional chemotherapy and radiotherapy. Nevertheless,
clinical relevance of soluble TRAIL (sTRAIL) has been
hampered by its short (< 1 h) pharmacokinetic half-life
in plasma, suggestive of relatively low protein stability,
as well as by its scavenging/partial elimination through
binding to antagonistic decoy receptors (DcR1 and
DcR2) expressed mainly by normal tissues which limit
its availability at tumor sites [261]. Again, as in the case
of IFN-β, local homing and delivery of TRAIL via
GM-MSC can overcome these problems. Indeed,
GM-MSC have been shown to successfully target and
significantly reduce tumor growth in models of multiple
myeloma [250], glioma/glioblastoma [232, 234, 235],
lung [226, 249, 253], liver [229, 252], colorectal [251],
and cervical [249] cancers. Among these are BM-MSC
and UC-MSC carrying human recombinant sTRAIL
against glioma/glioblastoma [232, 234] and hepatocarci-
noma [252], respectively. The significance of TRAIL as
an antitumor agent is highlighted by its inclusion in one
of the very first clinical trials involving MSC-based can-
cer gene therapy (NCT03298763; [262]). Set to begin in
2018, this phase I/II clinical trial focuses on the evalu-
ation of safety and antitumor activity of allogeneic
BM-MSC-TRAIL on up to 46 metastatic non-small cell
lung cancer (NSCLC) patients who are receiving
GM-MSC cytotherapy in conjunction with conventional
chemotherapy with pemetrexed/cisplatin. Interestingly,
the trial addresses the issues of BM-MSC adequacy and
variability by pooling cells from multiple donors before
transduction [1].
In the second strategy, GDEPT (also known as suicide
gene therapy), GM-MSC act as carriers of genes encod-
ing for specific enzymes that convert non-toxic prodrugs
into active derivatives [263]. The prodrugs are adminis-
tered systemically following in vivo infusion of
GM-MSC and homing towards tumor sites. The cyto-
toxic effect of the activated drug is then exerted locally
on cancer cells at the tumor site, thus minimizing
off-target toxicity; of course the production of drug me-
tabolites is also highly toxic for the MSC carriers them-
selves, which die in the process. The two enzyme/
prodrug combinations most widely used are herpes
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simplex virus thymidine kinase gene (HSV-tk)/ganciclo-
vir (GSV) and Escherichia coli cytosine deaminase (CD)/
5-fluorocytosine (5-FC), with suicide genes introduced
into the stem cell carriers via viral vectors (most often
retroviruses) (Table 4). One obvious advantage of
GDEPT over conventional cancer gene cytotherapy,
apart from the conditional rather than constitutive type
of action of the tumoricidal mechanism, is that it allows
the elimination of disseminated cells, thus acting as a
safety mechanism against any potential adverse effects
(e.g., transformation events) related to the long-term
persistence of homed and non-homed MSC in the pa-
tient’s body. Most importantly, the main benefit of this
anti-cancer approach is the amplification of the drug
toxic effects by means of bystander effect which is de-
scribed as the death of non-transfected cells (e.g., cancer
cells) due to indirect effects caused by their neighboring
transfected cells (MSC), causing more widespread cell
death than if transfected cells alone were killed [264,
265]. A requirement for this phenomenon is the active
or passive transference of the activated toxic metabolite
to neighboring cells which involves the use of gap junc-
tions [266, 267], endocytosis of apoptotic vesicles [265,
268], or paracrine effects that lead to immune system
stimulation [269, 270].
The two main GDEPT systems differ to the mechan-
ism by which they accomplish bystander effects and con-
sequently diverge in terms of their tumor growth
suppression efficiency. In the case of CD/5-FC system,
activated (deaminated) 5-FU rapidly crosses the plasma
membrane by passive diffusion and exerts its cytotoxic
effects by interfering with both DNA and RNA synthesis.
In contrast, the active phosphorylated form of GCV is a
charged metabolite unable to readily diffuse out of the
cell and thus relies on physical contact and gap junc-
tional intercellular communication (GJIC) between
therapeutic and tumor cell to exert its cytotoxic action
by interfering with DNA polymerase function. In the
case of CD/5-FC system, yeast or E. coli, the CD gene
can be used for the activation of 5-FC, although the bi-
functional fusion protein cytosine deaminase to uracil
phosphoribosyltransferase (CD::UPRT) is preferred due
to the higher bystander effect achieved in vitro and in
vivo. CD::UPRT chimeric protein not only exhibits an
enzymatic activity 10-fold greater than that of wild type
CD and increases sensitivity to 5-FC by at least 100-fold,
but also alleviates cytotoxicity resistance exhibited by
some tumors [271, 272].
Various studies have attempted to compare the efficacy of
CD::UPRT/5-FC and HSVtk-MSC/GCV systems (in the
absence or presence of MSC carriers). Whereas in the first
case, CD::UPRT/5-FC proves superior due to its greater
bystander effect, the effect on tumors targeted by
CD::UPRT-MSC/5-FC or HSVtk-MSC/GCV differs depend
ing on the expression status of enzymes of nucleotide metab-
olism and ATP-binding cassette (ABC) transporters, irre-
spective of GJIC status [239, 273, 274]. Thus, for example,
while both systems are equally effective against 8-MG-BA
gliomas, on the contrary, A375 melanoma and
MDA-MB-231 breast adenocarcinoma cells are differentially
sensitive to the two systems, with the former being more
susceptible to CD::UPRT-MSC/5-FC and more refractory to
HSVtk-MSC/GCV treatment, and vice versa.
TK/GCV and CD/5-FC GDEPT comprise the minority
of GM-MSC-based strategies, almost exclusively using
adult MSC as cellular vehicles (with AT-MSC used in
three out of four cases). Cancer types targeted include
melanomas [275], sarcomas [276], colon [277], prostate
[67, 278, 279], and ovarian [274]. The TK/GCV system
has been predominantly applied in combination with
AT-MSC for treating neural tumors demonstrating very
high efficacy [238, 239, 280]. Furthermore, in a phase I/
II clinical trial started in 2015, the very first one world-
wide to evaluate the safety and efficacy of GM-BM-MSC
against advanced, recurrent, or metastatic gastrointes-
tinal or hepatopancreatobiliary adenocarcinoma, the trial
methodology was based on intravenous injection of
HSV-tk-engineered MSC in patients, followed by re-
peated GCV injections [281].
It is worth highlighting that in some cases, in an effort to
maximize tumor suppression efficiency, a combination of
strategies is employed as evidenced for example in the case
of UC-MSC-IFN-β plus 5-FU (cytokine-transduced MSC +
chemotherapy drug) for the treatment of breast cancer [73],
UC-MSC-sTRAIL plus 5-FU (apoptosis agent-transduced
MSC + chemotherapy drug) [252], BM-MSC transduced
with sTRAIL plus HSVtk/GCV (apoptosis agent-transduced
MSC + GDEPT system) for glioblastoma treatment [231],
and HSVtk/GCV in combination with CD::UPRT/5-FC
(double GDEPT) used on AT-MSC against glioblastoma
[239] or breast-to-lung metastatic cancer [273]. These ap-
proaches result in various degrees of synergy, ranging from
mild, non-significant enhancement of tumor suppression, to
additive or stronger synergistic effects depending on the
tested cell line and experimental setup. For example, Matus-
kova and colleagues showed that sequential treatment (single
treatment with CD/5-FC followed by HSVtk/GCV) leads to
synergic cooperation of CD and HSVtk against
MDA-MB-231 metastases to lung, an effect that is stronger
at higher GCV doses [273].
Obviously, the multitude of combinations of antitumori-
genic molecular cargo, cellular vehicle, tumor model, gene
incorporation, and expression technology and method of
administration enables the generation of a large number of
individual GM-MSC-based anti-cancer strategies laying the
basis for personalized cancer cytotherapy. Interestingly, a
comparison of the different strategies applied in relation to
a specific cancer model frequently used in experimental
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cytotherapy studies reveals substantial accordance in the re-
sults obtained. For example, with respect to the popular
xenograft lung metastasis model, administration of human
GM-MSC in mice suppressed the metastases of human
MBA-MB-231 breast cells to the lung (determined by
measuring the increase in median survival of GM-
MSC-treated mice) by 62%, 81%, and 73% (72 ± 9.5%) for
BM-MSC-IFN-β [33], BM-MSC-TRAIL [226], or AT-MSC
receiving double GDEPT (CD::UPRT/5-FC : HSVtk/GCV,
1:1) [273], respectively. Similarly, metastases of MDA-
MB-231 breast cells were reduced by 53%, 42%, and 39%
(45 ± 7.4%) in mice receiving BM-MSC-IFN-β [33],
UC-MSC-IFN-β [72], or UC-MSC-IFN-β+5-FU combin-
ation treatment [73], respectively, as evidenced by the re-
duction of mouse lung masses one month after GM-MSC
administration.
Regardless of the strategy followed, successfully marry-
ing high efficacy with safety is the primary challenge in
developing a gene delivery system. So far all GM efforts
have relied on the heavy use of viral vectors (adeno-
virus—AV, retrovirus—RV, or lentivirus—LV). Generally,
viral vectors are more efficient at transferring genes than
non-viral vectors; however, clinical studies have revealed
that the efficacy of virus-mediated suicide gene therapy
was limited due to adverse effects, such as toxicity,
oncogenicity, and the possibility of invoking an excessive
antiviral host immune response [282]. For example, AV
expression is transient and often produces a signifi-
cant host immune response, whereas RV may cause
incorporation errors or even oncogene activation
[283, 284]. LV vectors are less likely to cause inser-
tional mutagenesis, since the promoter can be
Fig. 6 Tumor suppression rates (%) for genetically modified MSC (GM-MSC) in comparison to naïve MSC (n-MSC) and non-MSC controls.
Tumor suppression rates were determined using measured experimental outcomes (e.g., tumor size and weight, animal survival rate,
proliferation assays) derived from 20 selected publications in which the anti-cancer efficacy of genetically modified human MSC was
directly compared to that of unmodified, naïve MSC and non-MSC controls. a Whisker plots. Values next to whisker boxes depict median
values. b Tabular summary of the data plotted in a. Sample size (N) relates to total number of experimental readouts (e.g., tumor size
and weight, animal survival rate, proliferation assays) based on which % tumor suppression was calculated. P values correspond to t tests
comparing the specific groups
Christodoulou et al. Stem Cell Research & Therapy           (2018) 9:336 Page 26 of 38
modified extensively. Furthermore, they have the abil-
ity to stably transduce both dividing and quiescent
cells, which is a further significant advantage when
using stem cells that are often quiescent or slow
growing [285]. According to our analysis, LV is more
frequently associated with MSC transduced with
TRAIL (50% adoption rate compared to other antitu-
mor agents). In this setting, LV has been shown to ef-
ficiently and stably transduce MSC without affecting
their stemness, while at the same time, LV modifica-
tion does not result in altering DNA copy number
and arrangement in MSC [286]. Lately, advances in
genetic engineering methods have led to the develop-
ment of innovative non-viral nano-vectors that com-
bine the low toxicity and immunogenicity of cationic
liposomic carriers with the high transfection efficiency
of viral systems [287, 288].
Naïve MSC vs. GM-MSC-based cytotherapy efficacy
As mentioned earlier, GM-MSC-based cancer cytotherapy
has shown greater consistency in successfully suppressing
tumorigenesis. Nevertheless, the difference in tumor sup-
pression efficiency in comparison to n-MSC has been
largely discussed on a qualitative, rather than a quantitative
basis. Our meta-analysis approach gives for the first time,
to the best of our knowledge, a quantitative dimension to
the advantage of GM-MSC over n-MSC-based cancer
cytotherapy. With respect to the studies using GM-MSC,
they all report attenuation of tumor growth, irrespective of
the type of MSC effector, tumor target, GM strategy, or ani-
mal/culture model applied. On the contrary, as previously
discussed, the frequency of n-MSC studies showing a sig-
nificant onco-suppressive effect varies greatly (26–88%,
mean = 48%) depending on the type of MSC employed
(Fig. 3c). In other words, n-MSC-based cancer cytotherapy
is more “hit-or-miss” in terms of reliability with the final
outcome largely dependent on the MSC-tumor combin-
ation. In an effort to verify this observation and to provide
a more accurate quantitative estimate of the impact of
GM-MSC over n-MSC, we focused our meta-analysis on
experimental data from selected studies referring to experi-
mental cytotherapy work on human lung, breast and brain
cancers, in which human GM-MSC (of BM, AT, or UC ori-
gin) had been directly compared to n-MSC as well as to
matched non-MSC controls within the same experimental
setup [72, 73, 128, 200, 226, 227, 229, 232–237, 241, 242,
273, 289]. Such experimental readouts relating to anti-cancer
efficacy included measurement of size and/or weight of the
developing tumors, as well as changes in animal survival
rates (in vivo), and determination of cell proliferation and/ or
viability (in vitro). The wider range of antitumor effects of
n-MSC is largely attributed to BM-MSC. For example, intra-
tumoral (intracranial) or systemic (intracarotid) administra-
tion of naïve BM-MSC in athymic mice with established
gliomas resulted in reduction in median survival of the mice
by 6 and 5 days (or by 20% and 16%), respectively, as com-
pared to controls. On the contrary, infusion of BM-MSC-
IFN-β via the same routes extended animal survival by 12
and 8 days (or by 29% and 20%), respectively, over the
U87-only control group [236]. Overall, according to our ana-
lysis the tumor suppression efficiency of GM-MSC is higher
by about 40% compared to that of n-MSC, as depicted by
the significant difference in mean and in median values of
the two groups (Fig. 6). A point worth highlighting is also
the fact that in vitro experimentation tends to generate
tumor suppression rates (GM-MSC/n-MSC) that are gener-
ally higher than those obtained using rodent tumor models;
this is particularly evident in the case of cancer cell apoptosis
evaluation in vitro, where GM-MSC show on average an
eightfold higher pro-apoptotic effect, compared to their un-
modified counterparts (data not shown). Nevertheless, the
therapeutic advantage of GM-MSC in vivo is strong, with
the latter extending, for example regarding median survival
time of tumor-bearing mice by an average of 16 days over
n-MSC, equivalent to a life extension by two to four years in
humans (data not shown).
Taking all the above into consideration, it can be de-
duced that GM-MSC exhibit greater antitumor efficiency
when used as delivery vehicles in comparison with
non-modified cells. For GM-BM-MSC, there is enough
preclinical evidence showing the efficacy of IFN-β on
solid tumor suppression to warrant the move to clinical
trials. Indeed, by mid-2019 a trial involving up to 21 pa-
tients with advanced ovarian cancer is expected to pro-
vide the first ever data on the maximum tolerability and
safety of MSC-IFN-β in humans (NCT02530047; [262]).
With respect to GM-AT-MSC, experimental cytotherapy
data so far are suggestive of an increased antitumor effi-
cacy in relation to gliomas, especially when combined
with a form of GDEPT. Last but not least, in the case of
UC-MSC, genetic modification can only enhance their
intrinsic suppressive action on tumor growth. Unfortu-
nately, large gaps in GM-UC-MSC work do not allow us
to have a more complete picture regarding their
anti-cancer performance against important cancers such
as colorectal and prostate. Nevertheless, preclinical data
so far suggest that breast and lung cancers comprise two
potential targets for GM-UC-MSC testing in humans.
The hypo-immunogenicity and non-tumorigenicity of
human UC-MSC are additional features acting in sup-
port of the adoption of the specific cellular vehicle, in an
allogeneic setting, for the transition from the bench to
the bedside.
Conclusions
In our effort to decode the diversity of MSC-based can-
cer cytotherapy outcomes, we methodically recorded
and analyzed experimental data reported in the relevant
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literature. Our approach, although carefully designed, is
far from perfect as it is based on a relatively limited
number of observations that restrict the statistical reso-
lution to the descriptive statistics level. Nevertheless, the
trends obtained are representative and agree with the lit-
erature. In summary, our findings allow the following
conclusions to be drawn: (a) more studies focusing on
frequently occurring tumors are needed. This holds
truth for both naïve and GM-MSC-based research work.
For example, experimental data on naïve MSC targeting
cancers such as hepatic, gastric and lung are rare, ren-
dering any attempt to evaluate the MSC performance
against the latter unsuccessful. Prioritizing these targets
will provide more information towards a deeper under-
standing of the biology of MSC: tumor interactions, at
the same time setting a solid basis for the development
of more efficient MSC engineering protocols. Special
emphasis should also be given on cancers for which
there are preliminary studies with encouraging data that
need confirmation, or there are no studies evaluating the
anti-cancer performance of specific MSC types. These
are pancreatic (naïve AT-/BM-MSC), colon and prostate
(naïve and GM-UC-MSC), and brain cancers
(GM-UC-MSC). (b) More attention should be paid to
experimental design and implementation to minimize
the technical heterogeneity, which comprises a major
contributor for inconsistencies and erratic outcomes ob-
served in experimental tumor cytotherapy. Experimental
parameters such as the use of multiple cell lines to rep-
resent each tumor target, the MSC to cancer cell ratio,
timing and mode of cell administration used, and, last
but not least, the type of animal model adopted are of
particular importance. (c) Genetic modification of MSC
offers a significant advantage in anti-cancer efficacy over
naïve MSC, successfully alleviating the bimodal effects
of some MSC populations against certain tumors shift-
ing the balance robustly toward tumor suppression and
can become the new standard once the enabling tech-
nologies become safer. More focused clinical trials are
needed towards this end. (d) Despite the omissions and
inconsistencies, a critical mass of data from available
studies so far suggest that the primary outcome of ex-
perimental cytotherapy is largely dictated by the biology
of the interaction of the specific effector MSC with its
target, with some MSC populations (e.g., UC-MSC) gen-
erating a strong and robust tumoricidal response against
specific tumors (e.g., breast), while others (BM-MSC)
are clearly unsuitable for use on the same target, since
they display pro-tumorigenic behavior (Tables 5 and 6).
Differences in antitumor efficacy of MSC are determined
by the dynamics of their interactions with tumor niche
components, which in turn are determined by their
phenotypic and functional traits (e.g., secretome profile,
senescence status, cell surface receptor expression
levels), and ultimately depend on the developmental ori-
gin of these cells. (e) While a single stem cell type with a
ubiquitous anti-cancer behavioral profile is unlikely to
exist, our analysis indicates that MSC derived from the
umbilical cord of the human fetus possess enhanced
antitumorigenic characteristics compared to adult MSC,
which are largely likely attributed to their unique immu-
nomodulatory profile as primitive stem cells.
At this stage, any attempt to give a detailed account of
the mediating mechanisms would be largely speculative,
given the lack of studies focusing on the in vivo immu-
nomodulatory effects of administered MSC within tu-
mors, and the inadequacy of the present experimental
models to recapitulate the multitude of highly plastic
and bidirectional interactions that take place. Neverthe-
less, data patterns emerging from this meta-analysis (as
discussed in the “Exploring the role of experimental pa-
rameters on MSC-based cancer cytotherapy outcome”
and “Linking MSC phenotypic differences to variation in
anti-cancer efficacy” sections) interpreted in the context
of co-culture experiments examining MSC-immune ef-
fector cell interactions or focusing on the interplay be-
tween various tumor stroma cell classes during
carcinogenesis can be summarized into a conceptual
Table 5 Summary of evidence-based cancer therapy by MSC as deduced by the meta-analysis of peer-reviewed experimental/
preclinical research studies
MSC MSC GM status # Tumor target Effect on tumor target Evidence in support
AT Modified (or naïve) Neural Suppression **
UC Naïve (or modified) Breast Suppression ***
UC Modified (or naïve) Lung Suppression **
BM Modified Neural Suppression **
BM Modified Lung Suppression **
BM Modified (or naïve) Pancreas Suppression *
BM Naïve Breast Promotion ***
BM Naïve Osteosarcoma Promotion *
# Primary or secondary/minor (in brackets) contribution of the genetic modification status of the MSC to the overall observed effect on tumor target
No. of studies *≥ 3, **≥ 6, ***≥ 10
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framework as follows: (i) Different types of exogenous
MSC exert variable, often opposing, effects on the same
types of tumor targets in vitro and in vivo. (ii) The
tumor-promoting/-suppressive effect of MSC may in-
volve direct contact with the components of the tumor
microenvironment or may rely on paracrine/juxtacrine
effects mediated by the secreted form of induced mole-
cules. (iii) The type and extent of immune response
regulation might be a function of the maturity and com-
position of the microenvironment as well as the differen-
tial sensitivity of various MSC types to these maturation
levels. (iv) In any case, in an effort to fulfil their primary
role of maintaining tissue homeostasis, MSC interfere
with innate and immune response both in vitro and in
vivo ultimately adopting a pro- or anti-inflammatory
phenotype [290]. (v) The inflammatory response shares
various molecular targets and signaling pathways with
the carcinogenic process, such as increased cell prolifer-
ation rate, apoptosis, and angiogenesis. MSC are able to
influence such cancer hallmarks by directly adopting a
polarized inflammatory phenotype themselves or by dir-
ectly polarizing infiltrating immune cells, most notably
macrophages, into M1 (proinflammatory) or M2 (anti--
inflammatory/immunosuppressive) types. (vi) Exogenous
adult MSC exhibit a propensity towards adoption of the
proinflammatory phenotype under the dictation of muta-
tionally corrupted cancer cells emitting signals (secreted
chemokines) deceivingly associated with epithelial injury
and infection. Once recruited into the tumor microenviron-
ment BM-MSC and AT-MSC are induced to differentiate
towards stromal TAF/CAF (activated myofibroblasts or
adipocytes, respectively) that further propagate tumor
development by providing mitogenic epithelial growth fac-
tors directly to cancer cells, by facilitating EMT or further
recruitment of immune cells ([291], references within).
Adult MSC may be more susceptible to transformation into
TAF due to their genomic instability (accumulated oxida-
tive damage) and elevated senescence status (shorter
telomeres). (vii) In vivo, fetal UC-MSC exhibit a more
robust anti-cancer behavior by sustaining a healthy micro-
environment by actively skewing immune responses to an
anti-inflammatory profile (involving TRL3—rather than
TLR4—ligation, emergence of T-reg and activation of
immune complexes), resembling events occurring during
tissue regeneration and resolution of inflammation. (viii) In
vitro data showing the strong anti-proliferative effect of
culture media containing secreted UC-MSC metabolic
products (secretome) against cancer cells suggest that
UC-MSC constitutively produce trophic factors that possess
intrinsic antitumor properties. The secretome alone can suf-
ficiently mount a strong dose- and time-dependent anti-pro-
liferative response against certain tumor cells mediated by
apoptosis signaling (Christodoulou and Goulielmaki, manu-
script in preparation). (ix) The unique antitumorigenic
properties of UC-MSC most likely are attributed to a key
combination of secreted molecules normally associated with
the structural and functional traits of the host organ tissue
and its specialized role in the feto-maternal interface (e.g.,
LIF/IL-6: stemness; HLA-G: immune tolerance; glycocalyx
matrix hyaluronan; structural integrity).
Overall, the marked anti-cancer efficacy of UC-MSC, in
addition to their “off-the-shelf” availability, which comprises
the relatively greater abundance (ease of isolation, enhanced
expansion potential) and safety (reduced risk of malignant
transformation and hypo-immunogenic profile which al-
lows them to be used in an allogeneic setup), compared to
their adult counterparts highlights UC-MSC as instrumen-
tal tools in cancer cytotherapy (Table 6). Clearly, the out-
come of clinical trials will be crucial before these promising
cells find their way into the clinic. Nevertheless, after al-
most two decades of experimentation, it seems that the
cancer cytotherapy field is slowly coming off age.
Additional files
Additional file 1: Figure S1. Comparison of research activity (peer-
reviewed journal articles) on selected cancer treatment options over the
last two decades. The four graphs (solid lines) depict the evolution of
publication rates of journal articles reporting research work in PubMed
on four types of therapies relative to cancer treatment (radiotherapy,
combination chemotherapy, immunotherapy, and MSC-based cytotherapy)
over a period of 20 years. Graphs are based on reported rates over seven 3-
year periods, with a forward projection of one period (dashed trend line). In all
four cases, the rates increase exponentially (y = a eb x); nevertheless, the growth
for cancer cytotherapy publications (purple) occurs at a relatively higher rate
as shown by the steeper trend line and higher value of b constant in the
respective equation. This publication rate for MSC-based cancer cytotherapy
studies has grown over sixfold faster, compared to that for combined
chemotherapy, for example, rising from 1:100 to 1:15 over the last decade. This
trend is suggestive of increased interest in this field that will most likely be
sustained in the near future. PubMed search filters: English only, research
articles only. (TIF 30030 kb)
Additional file 2: Figure S2. Overview of meta-analysis methodology
(TIF 12282 kb)
Additional file 3: Figure S3. Example of a database form used to
record experimental data used in the meta-analysis. Field titles correspond
to the parameters comprising each of the in vitro and in vivo experiments
as described in the methodology and results sections of the relevant articles.
(TIF 9196 kb)
Additional file 4: Figure S4. Distribution of the three most frequently
associated tumors in relation to MSC effectors. Sample sizes: adipose-
derived MSC (AT-MSC) = 32, bone marrow-derived MSC (BM-MSC) = 56,
umbilical cord-derived MSC (UC-MSC) = 34. (TIF 4256 kb)
Additional file 5: Figure S5. Comparison of distribution of anti-cancer
effects for naïve MSC vs. naïve MSC used as control cells for genetically
modified MSC-based cancer cytotherapy studies (Naïve + GM). Each of
the 100% stacked columns shows the relative distribution of anti-cancer
effect observed (anti- vs. pro-tumorigenic vs. neutral) (TIF 103676 kb)
Additional file 6: Figure S6. List and frequency distribution of studies
employing the use of genetically modified stem cells (GM-MSC) of
human adipose tissue (AT), bone marrow (BM), and fetal umbilical cord
(UC) matrix origin. In each row of the table, the length of black-gradient
filled horizontal bars is proportional to the total number of studies (value
within bar) relevant to specific GM-MSC/tumor combinations; the list of
respective citations is shown under the bars. Cancer types are ranked in
descending order of world incidence (see also Fig. 2). Only tumors whose
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use is described by three or more independent studies are shown. Arrows
at the beginning of each row of the table symbolize deviation of the
frequency of tumor targeted in experimental cytotherapy work from their
respective incidence/frequency of occurrence globally (yellow = difference
within 5%; green, up = difference > 5% in favor of cytotherapy—tumor
over-representation; red, down = difference of > 5% in favor of incidence—-
tumor under-representation). */**/# Studies referring to cervical cancer/
ovarian cancer/ use of UC-blood MSC, respectively. (TIF 9450 kb)
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